

George Bakris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7747227/publications.pdf>

Version: 2024-02-01

824
papers

102,628
citations

613

124
h-index

231

305
g-index

864
all docs

864
docs citations

864
times ranked

55936
citing authors

#	ARTICLE	IF	CITATIONS
1	The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>. JAMA - Journal of the American Medical Association, 2003, 289, 2560.	3.8	18,097
2	Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 2003, 42, 1206-1252.	1.3	11,852
3	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 2019, 380, 2295-2306.	13.9	3,760
4	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. New England Journal of Medicine, 2013, 369, 1327-1335.	13.9	2,261
5	2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease. Circulation, 2010, 121, e266-369.	1.6	1,994
6	Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. New England Journal of Medicine, 2008, 359, 2417-2428.	13.9	1,849
7	A Controlled Trial of Renal Denervation for Resistant Hypertension. New England Journal of Medicine, 2014, 370, 1393-1401.	13.9	1,848
8	Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease<SUBTITLE>Results From the AASK Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2002, 288, 2421.	3.8	1,792
9	Preserving renal function in adults with hypertension and diabetes: A consensus approach. American Journal of Kidney Diseases, 2000, 36, 646-661.	2.1	1,314
10	2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease. Journal of the American College of Cardiology, 2010, 55, e27-e129.	1.2	1,298
11	Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney International, 2007, 71, 31-38.	2.6	1,244
12	Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2020, 383, 2219-2229.	13.9	1,148
13	A Calcium Antagonist vs a Non-“Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2003, 290, 2805.	3.8	1,107
14	Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive Nephrosclerosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2001, 285, 2719.	3.8	861
15	Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease. New England Journal of Medicine, 2013, 369, 2492-2503.	13.9	844
16	Diabetic Kidney Disease: A Report From an ADA Consensus Conference. Diabetes Care, 2014, 37, 2864-2883.	4.3	781
17	Clinical Practice Guidelines for the Management of Hypertension in the Community. Journal of Clinical Hypertension, 2014, 16, 14-26.	1.0	768
18	Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension. JAMA - Journal of the American Medical Association, 2004, 292, 2227.	3.8	710

#	ARTICLE	IF	CITATIONS
19	Angiotensin-Converting Enzyme Inhibitor-Associated Elevations in Serum Creatinine. Archives of Internal Medicine, 2000, 160, 685-93.	4.3	679
20	Antihypertensive Therapy in the Presence of Proteinuria. American Journal of Kidney Diseases, 2007, 49, 12-26.	2.1	671
21	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet, The, 2015, 385, 2067-2076.	6.3	659
22	Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease. New England Journal of Medicine, 2010, 363, 918-929.	13.9	638
23	Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus. Circulation, 2007, 115, 114-126.	1.6	634
24	Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension, 2018, 72, e53-e90.	1.3	629
25	Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine, 2021, 385, 2252-2263.	13.9	599
26	Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Clinical Chemistry, 2011, 57, e1-e47.	1.5	583
27	Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients With Diabetes and Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2010, 304, 61.	3.8	578
28	Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care, 2007, 30, 162-172.	4.3	577
29	Baroreflex Activation Therapy Lowers Blood Pressure in Patients With Resistant Hypertension. Journal of the American College of Cardiology, 2011, 58, 765-773.	1.2	538
30	Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy. JAMA - Journal of the American Medical Association, 2015, 314, 884.	3.8	523
31	Patiomer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors. New England Journal of Medicine, 2015, 372, 211-221.	13.9	521
32	The pathogenesis of diabetic nephropathy. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 444-452.	2.9	498
33	Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet, The, 2010, 375, 1173-1181.	6.3	472
34	Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care, 2017, 40, 1273-1284.	4.3	462
35	Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal, 2015, 36, 219-227.	1.0	458
36	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes, 2017, 66, 241-255.	0.3	454

#	ARTICLE	IF	CITATIONS
37	Diabetic Kidney Disease: A Report From an ADA Consensus Conference. American Journal of Kidney Diseases, 2014, 64, 510-533.	2.1	439
38	ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. Journal of the American College of Cardiology, 2011, 57, 2037-2114.	1.2	419
39	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, The, 2019, 393, 1937-1947.	6.3	408
40	Thiazide Diuretics, Potassium, and the Development of Diabetes. Hypertension, 2006, 48, 219-224.	1.3	405
41	Effects of Blood Pressure Level on Progression of Diabetic Nephropathy<subtitle>Results From the RENAAL Study</subtitle>. Archives of Internal Medicine, 2003, 163, 1555.	4.3	399
42	Management of High Blood Pressure in Blacks. Hypertension, 2010, 56, 780-800.	1.3	398
43	Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). American Journal of Kidney Diseases, 2003, 42, 617-622.	2.1	395
44	Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Diabetes Care, 2011, 34, e61-e99.	4.3	389
45	6. Glycemic Targets: <i>Standards of Medical Care in Diabetesâ€™2022</i>. Diabetes Care, 2022, 45, S83-S96.	4.3	388
46	Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors. Journal of the National Cancer Institute, 2010, 102, 596-604.	3.0	381
47	ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. Circulation, 2011, 123, 2434-2506.	1.6	381
48	Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney International, 1996, 50, 1641-1650.	2.6	375
49	Effect of Patiomer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease. JAMA - Journal of the American Medical Association, 2015, 314, 151.	3.8	370
50	Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. American Journal of Kidney Diseases, 2018, 71, 851-865.	2.1	362
51	Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. European Heart Journal, 2022, 43, 474-484.	1.0	341
52	Resistant Hypertension. Journal of the American College of Cardiology, 2008, 52, 1749-1757.	1.2	304
53	The Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes. Diabetes Care, 2005, 28, 2686-2690.	4.3	283
54	10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetesâ€™2022</i>. Diabetes Care, 2022, 45, S144-S174.	4.3	282

#	ARTICLE	IF	CITATIONS
55	Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. <i>Kidney International</i> , 2009, 75, 1272-1277.	2.6	280
56	Catheter-Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPPLICITY HTN-3 Trial. <i>Clinical Cardiology</i> , 2012, 35, 528-535.	0.7	278
57	A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2009, 374, 1423-1431.	6.3	277
58	The Relationship Between Magnitude of Proteinuria Reduction and Risk of End-stage Renal Disease. <i>Archives of Internal Medicine</i> , 2005, 165, 947.	4.3	264
59	Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020, 97, 42-61.	2.6	260
60	Hypertension Awareness, Treatment, and Control in Chronic Kidney Disease. <i>American Journal of Medicine</i> , 2008, 121, 332-340.	0.6	250
61	Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. <i>European Heart Journal</i> , 2021, 42, 152-161.	1.0	249
62	Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. <i>Kidney International</i> , 1998, 54, 1283-1289.	2.6	246
63	Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. <i>Vascular Medicine</i> , 2002, 7, 35-43.	0.8	244
64	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1304-1317.	2.6	232
65	Prevalence of CKD and Comorbid Illness in Elderly Patients in the United States: Results From the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2010, 55, S23-S33.	2.1	230
66	ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure. <i>Kidney International</i> , 2000, 58, 2084-2092.	2.6	222
67	Chronic Kidney Disease Associated Mortality in Diastolic Versus Systolic Heart Failure: A Propensity Matched Study—The Digitalis Investigation Group study was conducted and supported by the National Heart, Lung, and Blood Institute in collaboration with the Digitalis Investigation Group Investigators. This manuscript was prepared using a limited access data set obtained by the National Heart, Lung, and Blood Institute and does not necessarily reflect the opinions or views of the Digitalis Investigation Gro. <i>American Journal of Cardiology</i> , 2007, 99, 393-398.	0.7	217
68	Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2010, 56, 77-85.	1.2	215
69	Baroreflex Activation Therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. <i>Journal of the American Society of Hypertension</i> , 2012, 6, 152-158.	2.3	212
70	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. <i>Circulation</i> , 2019, 140, 739-750.	1.6	211
71	Serum Potassium and Clinical Outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). <i>Circulation</i> , 2008, 118, 1643-1650.	1.6	209
72	Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection. <i>Kidney International</i> , 1992, 41, 912-919.	2.6	203

#	ARTICLE	IF	CITATIONS
73	Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy. <i>Circulation: Heart Failure</i> , 2014, 7, 51-58.	1.6	203
74	Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 330-339.	2.3	201
75	Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. <i>Circulation</i> , 2018, 138, 1537-1550.	1.6	200
76	Independent Components of Chronic Kidney Disease as a Cardiovascular Risk State. <i>Archives of Internal Medicine</i> , 2007, 167, 1122.	4.3	197
77	Protection of the kidney by thiazolidinediones: An assessment from bench to bedside. <i>Kidney International</i> , 2006, 70, 1223-1233.	2.6	194
78	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2017, 46, 462-472.	1.4	194
79	ACC/AHA Versus ESC/ESH on Hypertension Guidelines. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3018-3026.	1.2	193
80	Renal handling of albumin: A critical review of basic concepts and perspective. <i>American Journal of Kidney Diseases</i> , 2002, 39, 899-919.	2.1	192
81	Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension. <i>Hypertension</i> , 2011, 57, 413-420.	1.3	192
82	Differential effects of calcium antagonist subclasses on markers of nephropathy progression. <i>Kidney International</i> , 2004, 65, 1991-2002.	2.6	189
83	Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 990.	3.8	182
84	Advanced glycation end-product cross-link breakersA novel approach to cardiovascular pathologies related to the aging process. <i>American Journal of Hypertension</i> , 2004, 17, S23-S30.	1.0	180
85	Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic Syndrome. <i>Diabetes Care</i> , 2006, 29, 2592-2597.	4.3	175
86	Blood Pressure Control and Improved Cardiovascular Outcomes in the International Verapamil SR-Trandolapril Study. <i>Hypertension</i> , 2007, 50, 299-305.	1.3	174
87	KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Management of Blood Pressure in CKD. <i>American Journal of Kidney Diseases</i> , 2013, 62, 201-213.	2.1	174
88	Combination therapy in hypertension. <i>Journal of the American Society of Hypertension</i> , 2010, 4, 42-50.	2.3	173
89	Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Circulation</i> , 2021, 143, 540-552.	1.6	171
90	Divergent Results Using Clinic and Ambulatory Blood Pressures. <i>Hypertension</i> , 2010, 56, 824-830.	1.3	169

#	ARTICLE	IF	CITATIONS
91	11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes 2022. <i>Diabetes Care</i> , 2022, 45, S175-S184.	4.3	168
92	Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. <i>European Heart Journal</i> , 2013, 34, 1204-1214.	1.0	167
93	Beta blockers in the management of chronic kidney disease. <i>Kidney International</i> , 2006, 70, 1905-1913.	2.6	164
94	Impact of Renal Denervation on 24-Hour Ambulatory Blood Pressure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1071-1078.	1.2	164
95	Resistant hypertension—its identification and epidemiology. <i>Nature Reviews Nephrology</i> , 2013, 9, 51-58.	4.1	162
96	Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. <i>American Heart Journal</i> , 2008, 156, 277-283.	1.2	160
97	National Kidney Foundation's Kidney Early Evaluation Program (KEEP) Annual Data Report 2009: Executive Summary. <i>American Journal of Kidney Diseases</i> , 2010, 55, S1-S3.	2.1	160
98	Combination therapy in hypertension. <i>Journal of the American Society of Hypertension</i> , 2010, 4, 90-98.	2.3	156
99	Effects of Diltiazem or Lisinopril on Massive Proteinuria Associated with Diabetes Mellitus. <i>Annals of Internal Medicine</i> , 1990, 112, 707.	2.0	151
100	Microalbuminuria as a Risk Predictor in Diabetes: The Continuing Saga. <i>Diabetes Care</i> , 2014, 37, 867-875.	4.3	151
101	Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes. <i>Journal of Human Hypertension</i> , 2007, 21, 709-716.	1.0	150
102	Long-term Effects of Renin-Angiotensin System Blocking Therapy and a Low Blood Pressure Goal on Progression of Hypertensive Chronic Kidney Disease in African Americans. <i>Archives of Internal Medicine</i> , 2008, 168, 832.	4.3	149
103	Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. <i>European Heart Journal</i> , 2012, 33, 2782-2795.	1.0	148
104	Executive Summary: Kidney Early Evaluation Program (KEEP) 2007 Annual Data Report. <i>American Journal of Kidney Diseases</i> , 2008, 51, S1-S2.	2.1	147
105	Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. <i>Kidney International</i> , 2008, 73, 1303-1309.	2.6	147
106	The double challenge of resistant hypertension and chronic kidney disease. <i>Lancet</i> , The, 2015, 386, 1588-1598.	6.3	147
107	Predictors of Hyperkalemia Risk following Hypertension Control with Aldosterone Blockade. <i>American Journal of Nephrology</i> , 2009, 30, 418-424.	1.4	146
108	Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. <i>Kidney International</i> , 2005, 67, 1483-1488.	2.6	145

#	ARTICLE	IF	CITATIONS
109	Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. <i>Diabetes Care</i> , 2016, 39, 2304-2310.	4.3	142
110	A role for calcium in radiocontrast-induced reductions in renal hemodynamics. <i>Kidney International</i> , 1985, 27, 465-468.	2.6	141
111	Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl. <i>Journal of Cardiac Failure</i> , 2014, 20, 953-958.	0.7	139
112	EXamination of Cardiovascular Outcomes with AlogliptIN versus Standard of Care in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE). <i>American Heart Journal</i> , 2011, 162, 620-626.e1.	1.2	138
113	Position Statement Executive Summary: Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. <i>Diabetes Care</i> , 2011, 34, 1419-1423.	4.3	138
114	Effects of Different Calcium Antagonists on Proteinuria Associated with Diabetes Mellitus. <i>Annals of Internal Medicine</i> , 1990, 113, 987.	2.0	137
115	Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. <i>American Journal of Kidney Diseases</i> , 2008, 51, S30-S37.	2.1	137
116	Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. <i>Kidney International</i> , 2008, 74, 364-369.	2.6	135
117	Effect of patiomer on reducing serum potassium and preventing recurrent hyperkalemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. <i>European Journal of Heart Failure</i> , 2015, 17, 1057-1065.	2.9	134
118	Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. <i>Lancet, The</i> , 2013, 381, 537-545.	6.3	132
119	Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. <i>Kidney International</i> , 1993, 43, 1210-1218.	2.6	131
120	Effect of Calcium Channel or β -Blockade on the Progression of Diabetic Nephropathy in African Americans. <i>Hypertension</i> , 1997, 29, 744-750.	1.3	131
121	Heart failure as a cause for hospitalization in chronic dialysis patients. <i>American Journal of Kidney Diseases</i> , 2003, 41, 1267-1277.	2.1	129
122	Effects of Theophylline on Erythropoietin Production in Normal Subjects and in Patients with Erythrocytosis after Renal Transplantation. <i>New England Journal of Medicine</i> , 1990, 323, 86-90.	13.9	128
123	Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2014, 34, 333-339.	0.6	128
124	The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure. <i>Journal of Clinical Hypertension</i> , 2011, 13, 81-88.	1.0	127
125	Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019, 50, 345-356.	1.4	127
126	Antihypertensive Therapy and the Risk of Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2000, 342, 969-970.	13.9	125

#	ARTICLE	IF	CITATIONS
127	ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. <i>Journal of the American Society of Hypertension</i> , 2011, 5, 259-352.	2.3	125
128	International Expert Consensus Statement. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2031-2045.	1.2	124
129	Mechanisms Contributing to Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated with Bardoxolone Methyl. <i>American Journal of Nephrology</i> , 2014, 39, 499-508.	1.4	124
130	Hypokalemia and Outcomes in Patients With Chronic Heart Failure and Chronic Kidney Disease. <i>Circulation: Heart Failure</i> , 2010, 3, 253-260.	1.6	123
131	Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study. <i>American Journal of Nephrology</i> , 2018, 47, 40-47.	1.4	123
132	Chronic Kidney Disease as a Coronary Artery Disease Risk Equivalent. <i>Current Cardiology Reports</i> , 2013, 15, 340.	1.3	120
133	Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors. <i>Kidney International</i> , 1999, 56, 206-210.	2.6	117
134	2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients with Thoracic Aortic Disease. <i>Anesthesia and Analgesia</i> , 2010, 111, 279-315.	1.1	116
135	Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study Equations: Risk Factors for and Complications of CKD and Mortality in the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2011, 57, S9-S16.	2.1	116
136	Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril Study. <i>Hypertension</i> , 2004, 44, 637-642.	1.3	114
137	Exceptional early blood pressure control rates: The ACCOMPLISH trial. <i>Blood Pressure</i> , 2007, 16, 80-86.	0.7	114
138	Combination Therapy in Hypertension. <i>Journal of Clinical Hypertension</i> , 2011, 13, 146-154.	1.0	114
139	13. Older Adults: <i>Standards of Medical Care in Diabetes”2022</i>. <i>Diabetes Care</i> , 2022, 45, S195-S207.	4.3	114
140	Epidemiology of hypertensive kidney disease. <i>Nature Reviews Nephrology</i> , 2011, 7, 11-21.	4.1	113
141	Blood Pressure Components and End-stage Renal Disease in Persons With Chronic Kidney Disease. <i>Archives of Internal Medicine</i> , 2012, 172, 41.	4.3	112
142	Intensive Hemodialysis, Left Ventricular Hypertrophy, and Cardiovascular Disease. <i>American Journal of Kidney Diseases</i> , 2016, 68, S5-S14.	2.1	112
143	Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019, 50, 333-344.	1.4	112
144	Molecular mechanisms and therapeutic targets for diabetic kidney disease. <i>Kidney International</i> , 2022, 102, 248-260.	2.6	112

#	ARTICLE	IF	CITATIONS
145	Characterization and implications of the initial estimated glomerular filtration rate \hat{e} ™ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. <i>Kidney International</i> , 2021, 99, 750-762.	2.6	111
146	\hat{I} -Blocker Use in Long-term Dialysis Patients. <i>Archives of Internal Medicine</i> , 2004, 164, 2465.	4.3	109
147	Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. <i>American Heart Journal</i> , 2012, 163, 156-163.	1.2	108
148	Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy. <i>American Journal of Nephrology</i> , 2014, 40, 64-74.	1.4	106
149	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1128-1139.	3.0	106
150	An In-Depth Review of the Evidence Linking Dietary Salt Intake and Progression of Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2006, 26, 268-275.	1.4	105
151	Thiazide-Induced Dysglycemia. <i>Hypertension</i> , 2008, 52, 30-36.	1.3	105
152	Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus. <i>Mayo Clinic Proceedings</i> , 2011, 86, 444-456.	1.4	104
153	Executive Summary: Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. <i>Clinical Chemistry</i> , 2011, 57, 793-798.	1.5	104
154	Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. <i>European Heart Journal</i> , 2016, 38, ehw325.	1.0	104
155	Slowing Nephropathy Progression. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, S3-S10.	2.2	103
156	12-Month Blood Pressure Results of Catheter-Based Renal Artery Denervation for Resistant Hypertension. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1314-1321.	1.2	103
157	Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2366-2374.	0.4	100
158	Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring. <i>Journal of Clinical Hypertension</i> , 2011, 13, 467-472.	1.0	100
159	Blood Pressure Reduction: An Added Benefit of Sodium \hat{e} ™ Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2015, 38, 429-430.	4.3	99
160	Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. <i>Kidney International</i> , 1994, 46, 161-169.	2.6	98
161	Risk of Hyperkalemia in Nondiabetic Patients With Chronic Kidney Disease Receiving Antihypertensive Therapy<alt-title>Hyperkalemia in CKD Adults Using Antihypertensives</alt-title>. <i>Archives of Internal Medicine</i> , 2009, 169, 1587.	4.3	98
162	Pheochromocytoma in Pregnancy. <i>Hypertension</i> , 2010, 55, 600-606.	1.3	98

#	ARTICLE	IF	CITATIONS
163	Class differences in the effects of calcium channel blockers in the rat remnant kidney model. <i>Kidney International</i> , 1999, 55, 1849-1860.	2.6	97
164	Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. <i>American Journal of Hypertension</i> , 2004, 17, 793-801.	1.0	97
165	State of Hypertension Management in the United States: Confluence of Risk Factors and the Prevalence of Resistant Hypertension. <i>Journal of Clinical Hypertension</i> , 2008, 10, 130-139.	1.0	97
166	The past, present and future of renin-angiotensin aldosterone system inhibition. <i>International Journal of Cardiology</i> , 2013, 167, 1677-1687.	0.8	97
167	Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy. <i>Hypertension</i> , 2017, 69, 836-843.	1.3	96
168	Body Weight Changes with β -Blocker Use: Results from GEMINI. <i>American Journal of Medicine</i> , 2007, 120, 610-615.	0.6	95
169	Prevalence and Associations of Anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. <i>American Journal of Kidney Diseases</i> , 2008, 51, S46-S55.	2.1	95
170	Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c $\geq 7\%$. <i>Circulation</i> , 2020, 141, 407-410.	1.6	95
171	Abnormalities of Potassium in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2836-2850.	1.2	94
172	Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. <i>Kidney International</i> , 1998, 54, 889-896.	2.6	93
173	Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial. <i>Kidney International</i> , 2007, 72, 879-885.	2.6	93
174	Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. <i>Kidney International</i> , 2021, 99, 999-1009.	2.6	93
175	Insulin and Endothelin: An Interplay Contributing to Hypertension Development?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 379-385.	1.8	92
176	Association between hyperuricemia and incident heart failure among older adults: A propensity-matched study. <i>International Journal of Cardiology</i> , 2010, 142, 279-287.	0.8	92
177	Patiomer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. <i>Kidney International</i> , 2015, 88, 1427-1433.	2.6	90
178	The importance of blood pressure control in the patient with diabetes. <i>American Journal of Medicine</i> , 2004, 116, 30-38.	0.6	89
179	Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 225-237.	3.0	89
180	Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. <i>Journal of Hypertension</i> , 2006, 24, 2047-2055.	0.3	88

#	ARTICLE	IF	CITATIONS
181	Efficacy and Safety of Darusentan in Patients With Resistant Hypertension: Results From a Randomized, Double-blind, Placebo-controlled Dose-ranging Study. <i>Journal of Clinical Hypertension</i> , 2007, 9, 760-769.	1.0	88
182	Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. <i>Journal of Hypertension</i> , 2014, 32, 635-643.	0.3	88
183	Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. <i>Circulation</i> , 2022, 145, 575-585.	1.6	88
184	Redefining Hypertension – Assessing the New Blood-Pressure Guidelines. <i>New England Journal of Medicine</i> , 2018, 378, 497-499.	13.9	87
185	Effects of Canagliflozin in Patients with Baseline eGFR $\leq 30\text{ ml/min per }1.73\text{ m}^2$. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1705-1714.	2.2	87
186	Mineralocorticoid receptor antagonists in diabetic kidney disease – mechanistic and therapeutic effects. <i>Nature Reviews Nephrology</i> , 2022, 18, 56-70.	4.1	87
187	12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes 2022. <i>Diabetes Care</i> , 2022, 45, S185-S194.	4.3	87
188	Pathogenesis and Clinical Physiology of Hypertension. <i>Cardiology Clinics</i> , 2010, 28, 545-559.	0.9	86
189	Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. <i>Circulation</i> , 2022, 145, 437-447.	1.6	86
190	Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. <i>Journal of Hypertension</i> , 2002, 20, 2257-2267.	0.3	85
191	Amlodipine and Valsartan Combined and as Monotherapy in Stage 2, Elderly, and Black Hypertensive Patients: Subgroup Analyses of 2 Randomized, Placebo-Controlled Studies. <i>Journal of Clinical Hypertension</i> , 2007, 9, 355-364.	1.0	85
192	A Practical Approach to Achieving Recommended Blood Pressure Goals in Diabetic Patients. <i>Archives of Internal Medicine</i> , 2001, 161, 2661.	4.3	82
193	Achieving Goal Blood Pressure in Patients With Type 2 Diabetes: Conventional Versus Fixed-Dose Combination Approaches. <i>Journal of Clinical Hypertension</i> , 2003, 5, 202-209.	1.0	82
194	Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON). <i>American Journal of Nephrology</i> , 2013, 37, 212-222.	1.4	82
195	A Trial of 2 Strategies to Reduce Nocturnal Blood Pressure in Blacks With Chronic Kidney Disease. <i>Hypertension</i> , 2013, 61, 82-88.	1.3	82
196	Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/insulin resistance?. <i>Journal of Human Hypertension</i> , 2007, 21, 12-19.	1.0	81
197	Renal function and target organ damage in hypertension. <i>European Heart Journal</i> , 2011, 32, 1599-1604.	1.0	81
198	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. <i>European Heart Journal</i> , 2021, 42, 4891-4901.	1.0	80

#	ARTICLE	IF	CITATIONS
199	Effects of Sodium Intake on Albumin Excretion in Patients with Diabetic Nephropathy Treated with Long-Acting Calcium Antagonists. <i>Annals of Internal Medicine</i> , 1996, 125, 201.	2.0	79
200	Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. <i>Kidney International</i> , 2000, 57, 1651-1661.	2.6	79
201	SGLT2 Inhibitors and Mechanisms of Hypertension. <i>Current Cardiology Reports</i> , 2018, 20, 1.	1.3	78
202	Differential Effects of \hat{I}^2 -Blockers on Albuminuria in Patients With Type 2 Diabetes. <i>Hypertension</i> , 2005, 46, 1309-1315.	1.3	76
203	The Efficacy and Safety of Low- and High- Dose Fixed Combinations of Irbesartan/Hydrochlorothiazide in Patients With Uncontrolled Systolic Blood Pressure on Monotherapy: The INCLUSIVE Trial. <i>Journal of Clinical Hypertension</i> , 2005, 7, 578-586.	1.0	75
204	Comparison of Measured GFR, Serum Creatinine, Cystatin C, and Beta-Trace Protein to Predict ESRD in African Americans With Hypertensive CKD. <i>American Journal of Kidney Diseases</i> , 2011, 58, 886-893.	2.1	74
205	Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2021, 78, 142-152.	1.2	74
206	Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 903-914.	5.5	73
207	Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy. <i>Kidney International Reports</i> , 2022, 7, 36-45.	0.4	73
208	Association of NEDD4L Ubiquitin Ligase With Essential Hypertension. <i>Hypertension</i> , 2005, 46, 488-491.	1.3	72
209	Effects of Drospirenone/17- \hat{I}^2 Estradiol on Blood Pressure and Potassium Balance in Hypertensive Postmenopausal Women. <i>American Journal of Hypertension</i> , 2005, 18, 797-804.	1.0	72
210	Redefining diuretics use in hypertension. <i>Journal of Hypertension</i> , 2019, 37, 1574-1586.	0.3	72
211	Antihypertensive Efficacy of Hydrochlorothiazide vs Chlorthalidone Combined with Azilsartan Medoxomil. <i>American Journal of Medicine</i> , 2012, 125, 1229.e1-1229.e10.	0.6	71
212	BP Control and Long-Term Risk of ESRD and Mortality. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 671-677.	3.0	71
213	The Antinatriuretic Effect of Insulin: An Unappreciated Mechanism for Hypertension Associated with Insulin Resistance?. <i>American Journal of Nephrology</i> , 2007, 27, 44-54.	1.4	70
214	Microalbuminuria: What Is It? Why Is It Important? What Should Be Done about It?. <i>Journal of Clinical Hypertension</i> , 2001, 3, 99-102.	1.0	69
215	Renin-Angiotensin Inhibition in Systolic Heart Failure and Chronic Kidney Disease. <i>American Journal of Medicine</i> , 2012, 125, 399-410.	0.6	69
216	Predictors of Development of Diabetes Mellitus in Patients With Coronary Artery Disease Taking Antihypertensive Medications (Findings from the International Verapamil SR-Trandolapril Study)	0.0	68

#	ARTICLE	IF	CITATIONS
217	Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection. <i>Blood Pressure</i> , 2005, 14, 196-209.	0.7	67
218	Effect of Aliskiren on Progression of Coronary Disease in Patients With Prehypertension. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1135.	3.8	67
219	Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006, 99, 431-436.	0.2	66
220	Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease. <i>Journal of Hypertension</i> , 2019, 37, 2307-2324.	0.3	66
221	Arginine vasopressin stimulates human mesangial cell production of endothelin.. <i>Journal of Clinical Investigation</i> , 1991, 87, 1158-1164.	3.9	66
222	Effects of COX Inhibition on Blood Pressure and Kidney Function in ACE Inhibitor-Treated Blacks and Hispanics. <i>Hypertension</i> , 2004, 43, 573-577.	1.3	65
223	Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk. <i>Blood Pressure</i> , 2007, 16, 13-19.	0.7	65
224	Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. <i>British Journal of Pharmacology</i> , 2022, 179, 3220-3234.	2.7	65
225	Impact of Renal Denervation on Patients With Obstructive Sleep Apnea and Resistant Hypertension—Insights From the SYMPPLICITY HTN-3 Trial. <i>Circulation Journal</i> , 2016, 80, 1404-1412.	0.7	64
226	ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. <i>Journal of Diabetes and Its Complications</i> , 1994, 8, 2-6.	1.2	63
227	Microalbuminuria: prognostic implications. <i>Current Opinion in Nephrology and Hypertension</i> , 1996, 5, 219-223.	1.0	63
228	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. <i>Seminars in Nephrology</i> , 2004, 24, 168-175.	0.6	63
229	New Potassium Binders for the Treatment of Hyperkalemia. <i>Hypertension</i> , 2015, 66, 731-738.	1.3	63
230	From epidemiological transition to modern cardiovascular epidemiology: hypertension in the 21st century. <i>Lancet, The</i> , 2016, 388, 530-532.	6.3	63
231	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. <i>Diabetes Care</i> , 2020, 43, 446-452.	4.3	63
232	Calcium Antagonists. <i>Hypertension</i> , 2005, 46, 637-642.	1.3	62
233	G-Protein-Coupled Receptor Kinase 4 Polymorphisms and Blood Pressure Response to Metoprolol Among African Americans: Sex-Specificity and Interactions. <i>American Journal of Hypertension</i> , 2009, 22, 332-338.	1.0	62
234	The Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure. <i>Circulation</i> , 2016, 134, 904-905.	1.6	62

#	ARTICLE	IF	CITATIONS
235	Hypertensive nephropathy: prevention and treatment recommendations. Expert Opinion on Pharmacotherapy, 2010, 11, 2675-2686.	0.9	61
236	Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes, Obesity and Metabolism, 2018, 20, 1369-1376.	2.2	60
237	Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 1027-1036.	2.6	60
238	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease. Circulation, 2021, 143, 1735-1749.	1.6	60
239	Azilsartan Medoxomil Plus Chlorthalidone Reduces Blood Pressure More Effectively Than Olmesartan Plus Hydrochlorothiazide in Stage 2 Systolic Hypertension. Hypertension, 2012, 60, 310-318.	1.3	59
240	Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study. Hypertension, 2021, 78, 74-81.	1.3	59
241	Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. American Heart Journal, 2006, 151, 176-184.	1.2	58
242	Uncontrolled hypertension and increased risk for incident heart failure in older adults with hypertension: findings from a propensity-matched prospective population study. Journal of the American Society of Hypertension, 2010, 4, 22-31.	2.3	58
243	Microalbuminuria. Clinics in Laboratory Medicine, 2006, 26, 635-653.	0.7	56
244	Systolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension. American Journal of Medicine, 2013, 126, 501-508.	0.6	56
245	Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly?. Stroke, 2007, 38, 441-450.	1.0	55
246	Efficacy and Duration of Benazepril Plus Amlodipine or Hydrochlorothiazide on 24-Hour Ambulatory Systolic Blood Pressure Control. Hypertension, 2011, 57, 174-179.	1.3	55
247	Association of BP Variability with Mortality among African Americans with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 731-738.	2.2	55
248	Review of blood pressure control rates and outcomes. Journal of the American Society of Hypertension, 2014, 8, 127-141.	2.3	55
249	Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney International, 2016, 90, 696-704.	2.6	55
250	Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin) Tj ETQq0 0 0 rgBT /Overlook 10 Tf 5	1.6	54
251	Awareness of Kidney Disease and Relationship to End-stage Renal Disease and Mortality. American Journal of Medicine, 2012, 125, 661-669.	0.6	53
252	Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: <sc>T</sc>he <sc>EXAMINE</sc> trial. Diabetes, Obesity and Metabolism, 2017, 19, 664-671.	2.2	53

#	ARTICLE	IF	CITATIONS
253	Race and Sex Differences in Hypertension Control in CKD: Results From the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2008, 51, 192-198.	2.1	52
254	Acute Interstitial Nephritis with Glomerulopathy Due to Nonsteroidal Anti-inflammatory Agents: A Review of Its Clinical Spectrum and Effects of Steroid Therapy. <i>Journal of Clinical Pharmacology</i> , 1990, 30, 468-475.	1.0	51
255	Efficacy and Safety of Coadministered Amlodipine and Atorvastatin in Patients With Hypertension and Dyslipidemia: Results of the AVALON Trial. <i>Journal of Clinical Hypertension</i> , 2006, 8, 571-583.	1.0	51
256	Renin-angiotensin blockade and kidney disease. <i>Lancet</i> , 2008, 372, 511-512.	6.3	51
257	Blood Pressure, Hypertension, RAAS Blockade, and Drug Therapy in Diabetic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 281-286.	0.6	51
258	Effect of Ruboxistaurin on Urinary Transforming Growth Factor- β in Patients With Diabetic Nephropathy and Type 2 Diabetes. <i>Diabetes Care</i> , 2007, 30, 995-996.	4.3	50
259	Regression to the Mean in SYMPLICITY-HTN-3. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2016-2025.	1.2	50
260	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1379-1390.	1.2	50
261	Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1014-1023.	0.4	50
262	Antihypertensive Efficacy of Candesartan in Comparison to Losartan: The CLAIM Study. <i>Journal of Clinical Hypertension</i> , 2001, 3, 16-21.	1.0	49
263	Control of Blood Pressure and Other Cardiovascular Risk Factors at Different Practice Settings: Outcomes of Care Provided to Diabetic Women Compared to Men. <i>Journal of Clinical Hypertension</i> , 2005, 7, 73-80.	1.0	49
264	Are Chlorthalidone and Hydrochlorothiazide Equivalent Blood Pressure Lowering Medications?. <i>Journal of Clinical Hypertension</i> , 2005, 7, 354-356.	1.0	49
265	ASH Position Paper: Treatment of Hypertension in Patients With Diabetes—An Update. <i>Journal of Clinical Hypertension</i> , 2008, 10, 707-713.	1.0	49
266	Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: The ACCOMPLISH Study. <i>Blood Pressure</i> , 2008, 17, 7-17.	0.7	49
267	Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 234-238.	2.2	49
268	Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension. <i>Journal of Hypertension</i> , 2012, 30, 874-876.	0.3	49
269	National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. <i>Kidney International</i> , 2010, 78, 726-736.	2.6	48
270	Mild hyperkalemia and outcomes in chronic heart failure: A propensity matched study. <i>International Journal of Cardiology</i> , 2010, 144, 383-388.	0.8	48

#	ARTICLE	IF	CITATIONS
271	Individualizing Blood Pressure Targets for People With Diabetes and Hypertension. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1319.	3.8	48
272	Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis. <i>Current Hypertension Reports</i> , 2019, 21, 12.	1.5	48
273	Design of the COmbination effect of Flnerenone and Empagliflozin in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 894-903.	0.4	48
274	Comparative Effects of Selective T- and L-Type Calcium Channel Blockers in the Remnant Kidney Model. <i>Hypertension</i> , 2001, 37, 1268-1272.	1.3	47
275	Comparison of Commonly Used Assays for the Detection of Microalbuminuria. <i>Journal of Clinical Hypertension</i> , 2004, 6, 8-12.	1.0	47
276	<i><i>CYP3A4</i> and <i>CYP3A5</i> Polymorphisms and Blood Pressure Response to Amlodipine among African-American Men and Women with Early Hypertensive Renal Disease. <i>American Journal of Nephrology</i> , 2010, 31, 95-103.	1.4	47
277	Kidney Early Evaluation Program: A Community-Based Screening Approach to Address Disparities in Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2010, 30, 66-73.	0.6	47
278	Renal denervation for the treatment of resistant hypertension: review and clinical perspective. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, F583-F594.	1.3	47
279	Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. <i>Diabetes Care</i> , 2016, 39, 1267-1273.	4.3	47
280	Effects of Thiazolidinediones Beyond Glycaemic Control. <i>Current Pharmaceutical Design</i> , 2009, 15, 529-536.	0.9	46
281	Detection, evaluation, and treatment of severe and resistant hypertension. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 743-757.	2.3	45
282	Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-ON. <i>ESC Heart Failure</i> , 2018, 5, 592-602.	1.4	45
283	Type 2 Diabetes: RENAAL and IDNT-The Emergence of New Treatment Options. <i>Journal of Clinical Hypertension</i> , 2002, 4, 52-57.	1.0	44
284	Combined Therapy With a Calcium Channel Blocker and an Angiotensin II Type 1 Receptor Blocker. <i>Journal of Clinical Hypertension</i> , 2008, 10, 27-32.	1.0	44
285	Are There Effects of Renin-Angiotensin System Antagonists Beyond Blood Pressure Control?. <i>American Journal of Cardiology</i> , 2010, 105, 21A-29A.	0.7	44
286	Isolated Diastolic Hypotension and Incident Heart Failure in Older Adults. <i>Hypertension</i> , 2011, 58, 895-901.	1.3	44
287	Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. <i>Journal of Human Hypertension</i> , 2013, 27, 479-486.	1.0	44
288	Angiotensin-Converting Enzyme Inhibitors and Progression of Diabetic Nephropathy. <i>Annals of Internal Medicine</i> , 1993, 118, 643.	2.0	43

#	ARTICLE	IF	CITATIONS
289	Therapeutic challenges in the obese diabetic patient with hypertension. <i>American Journal of Medicine</i> , 1996, 101, 33S-46S.	0.6	43
290	Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study. <i>Journal of Human Hypertension</i> , 2002, 16, 185-191.	1.0	43
291	Clinical importance of microalbuminuria in diabetes and hypertension. <i>Current Hypertension Reports</i> , 2004, 6, 352-356.	1.5	43
292	Cardiometabolic Syndrome and Chronic Kidney Disease: What Is the Link?. <i>Journal of the Cardiometabolic Syndrome</i> , 2006, 1, 58-65.	1.7	43
293	A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure. <i>International Journal of Cardiology</i> , 2009, 137, 1-8.	0.8	43
294	The Kidney, Hypertension, and Remaining Challenges. <i>Medical Clinics of North America</i> , 2009, 93, 697-715.	1.1	43
295	Malnutrition-Inflammation Modifies the Relationship of Cholesterol with Cardiovascular Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 2131-2142.	3.0	43
296	Oxygen free radical involvement in urinary Tamm-Horsfall protein excretion after intrarenal injection of contrast medium.. <i>Radiology</i> , 1990, 175, 57-60.	3.6	42
297	Gender disparity in outcomes of care and management for diabetes and the metabolic syndrome. <i>Current Diabetes Reports</i> , 2006, 6, 219-224.	1.7	42
298	Antihypertensive agents, insulin sensitivity, and new-onset diabetes. <i>Current Diabetes Reports</i> , 2007, 7, 191-199.	1.7	42
299	CKD Awareness in the United States: The Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2008, 52, 382-383.	2.1	42
300	Association of Race and Body Mass Index With ESRD and Mortality in CKD Stages 3-4: Results From the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2013, 61, 404-412.	2.1	42
301	Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure. <i>Hypertension</i> , 2015, 66, 1130-1137.	1.3	42
302	Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3939-3985.	1.8	42
303	Maximizing Cardiorenal Benefit in the Management of Hypertension: Achieve Blood Pressure Goals. <i>Journal of Clinical Hypertension</i> , 1999, 1, 141-147.	1.0	42
304	Lessons Learned from Recent Hypertension Trials about Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 229-235.	2.2	41
305	Limitations of metformin use in patients with kidney disease: are they warranted?. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 1079-1083.	2.2	41
306	Blood Pressure—Lowering Efficacy of the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone: A Factorial Study. <i>Journal of Clinical Hypertension</i> , 2012, 14, 284-292.	1.0	41

#	ARTICLE	IF	CITATIONS
307	Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by <sc>GLP-1 RA</sc> treatment: A subgroup analysis from the <sc>FIDELIO-DKD</sc> trial. Diabetes, Obesity and Metabolism, 2022, 24, 125-134.	2.2	41
308	Prehypertension: is it relevant for nephrologists?. Kidney International, 2010, 77, 194-200.	2.6	40
309	The association of interdialytic blood pressure variability with cardiovascular events and all-cause mortality in haemodialysis patients. Nephrology Dialysis Transplantation, 2019, 34, 515-523.	0.4	40
310	Antihypertensive Efficacy of Irbesartan/HCTZ in Men and Women With the Metabolic Syndrome and Type 2 Diabetes. Journal of Clinical Hypertension, 2006, 8, 470-480.	1.0	39
311	Microalbuminuria: What Is It? Why Is It Important? What Should Be Done About It? An Update. Journal of Clinical Hypertension, 2007, 9, 196-200.	1.0	39
312	Hypertension in patients with diabetes. Postgraduate Medicine, 2000, 107, 29-38.	0.9	38
313	Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management. Journal of Human Hypertension, 2000, 14, 667-685.	1.0	38
314	Therapeutic approaches to achieve desired blood pressure goals: focus on calcium channel blockers. , 2000, 14, 295-301.		38
315	Gestational Diabetes Mellitus Alone in the Absence of Subsequent Diabetes Is Associated With Microalbuminuria. Diabetes Care, 2010, 33, 2586-2591.	4.3	38
316	Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors. American Journal of Medicine, 2018, 131, 555-564.e3.	0.6	38
317	Diabetic nephropathy. Postgraduate Medicine, 1993, 93, 89-100.	0.9	37
318	A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. American Journal of Hypertension, 2002, 15, 53-57.	1.0	37
319	Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial. Blood Pressure Monitoring, 2005, 10, 157-163.	0.4	37
320	Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use. American Journal of Kidney Diseases, 2016, 68, S15-S23.	2.1	37
321	Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk. Journal of the American Society of Nephrology: JASN, 2017, 28, 2794-2801.	3.0	37
322	Novel therapies for diabetic kidney disease. Kidney International Supplements, 2018, 8, 18-25.	4.6	37
323	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 384-395.	2.2	37
324	Pulmonary scar carcinoma a clinicopathologic analysis. Cancer, 1983, 52, 493-497.	2.0	36

#	ARTICLE	IF	CITATIONS
325	Development of explicit criteria to measure adherence to hypertension guidelines. <i>Journal of Human Hypertension</i> , 2006, 20, 426-433.	1.0	36
326	A Comparative Evaluation of Various Methods for Microalbuminuria Screening. <i>American Journal of Nephrology</i> , 2008, 28, 324-329.	1.4	36
327	An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPPLICITY HTN-3 trial. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 769-779.	2.3	36
328	An In-depth Analysis of Vasodilation in the Management of Hypertension: Focus on Adrenergic Blockade. <i>Journal of Cardiovascular Pharmacology</i> , 2009, 53, 379-387.	0.8	35
329	Novel therapies of diabetic nephropathy. <i>Current Opinion in Nephrology and Hypertension</i> , 2009, 18, 107-111.	1.0	34
330	Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. <i>European Journal of Heart Failure</i> , 2017, 19, 792-799.	2.9	34
331	Recognition and management of masked hypertension: A review and novel approach. <i>Journal of the American Society of Hypertension</i> , 2013, 7, 244-252.	2.3	33
332	Renal Denervation for Resistant Hypertension. <i>New England Journal of Medicine</i> , 2014, 371, 182-184.	13.9	33
333	Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy. <i>American Journal of Nephrology</i> , 2014, 40, 572-581.	1.4	33
334	On-Treatment Blood Pressure and Cardiovascular Outcomes in Older Adults With Isolated Systolic Hypertension. <i>Hypertension</i> , 2017, 69, 220-227.	1.3	33
335	MASKed-unconTrolled hypERTension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol. <i>BMJ Open</i> , 2018, 8, e021038.	0.8	33
336	Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 604-617.	2.9	33
337	Hypertension in Diabetic Patients An Overview of Interventional Studies to Preserve Renal Function. <i>American Journal of Hypertension</i> , 1993, 6, 140S-147S.	1.0	32
338	Slowing the progression of diabetic nephropathy and its cardiovascular consequences. <i>American Heart Journal</i> , 2004, 148, 243-251.	1.2	32
339	Should β -Blockers Be Used to Control Hypertension in People With Chronic Kidney Disease?. <i>Seminars in Nephrology</i> , 2007, 27, 555-564.	0.6	32
340	Randomized Study of Antihypertensive Efficacy and Safety of Combination Aliskiren/Valsartan vs Valsartan Monotherapy in Hypertensive Participants With Type 2 Diabetes Mellitus. <i>Journal of Clinical Hypertension</i> , 2013, 15, 92-100.	1.0	32
341	Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory <i>post hoc</i> analyses from FIDELIO-DKD compared to reported CREDENCE results. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1261-1269.	0.4	32
342	Benefits of combination angiotensin- converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. <i>American Journal of Hypertension</i> , 1999, 12, 80-85.	1.0	31

#	ARTICLE	IF	CITATIONS
343	Barriers to blood pressure control in African Americans. <i>Postgraduate Medicine</i> , 2002, 112, 51-70.	0.9	31
344	Efficacy of a Once-Daily Formulation of Carvedilol for the Treatment of Hypertension. <i>Journal of Clinical Hypertension</i> , 2006, 8, 840-849.	1.0	31
345	Risk factor assessment for new onset diabetes: literature review. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 177-187.	2.2	31
346	Interaction between Adiponectin and Aldosterone. <i>CardioRenal Medicine</i> , 2011, 1, 96-101.	0.7	31
347	Renal outcomes in hypertensive Black patients at high cardiovascular risk. <i>Kidney International</i> , 2012, 81, 568-576.	2.6	31
348	Advances in treatment of hyperkalemia in chronic kidney disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2205-2215.	0.9	31
349	The evolution of antihypertensive therapy: An overview of four decades of experience. <i>Journal of the American College of Cardiology</i> , 1989, 14, 1595-1608.	1.2	30
350	ACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What's the Evidence?. <i>Journal of Clinical Hypertension</i> , 2002, 4, 420-440.	1.0	30
351	Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trialThe first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. <i>American Journal of Hypertension</i> , 2004, 17, 793-801.	1.0	30
352	Controlled-Release Carvedilol in the Treatment of Essential Hypertension. <i>American Journal of Cardiology</i> , 2006, 98, 32-38.	0.7	30
353	Mechanistic Insights into Diuretic-Induced Insulin Resistance. <i>Hypertension</i> , 2008, 52, 1009-1011.	1.3	30
354	Pathogenesis and Treatment of Microalbuminuria in Patients With Diabetes: The Road Ahead. <i>Journal of Clinical Hypertension</i> , 2009, 11, 636-643.	1.0	30
355	Hypertension in Early-Stage Kidney Disease: An Update From the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2009, 53, S22-S31.	2.1	30
356	Determinants and Changes Associated with Aldosterone Breakthrough after Angiotensin II Receptor Blockade in Patients with Type 2 Diabetes with Overt Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1694-1701.	2.2	30
357	High sensitivity C-reactive protein, low density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Tj ETQq1 1 0.784314 rgBT /Overlock 10 Metabolism. 2018, 20, 654-659.	2.2	30
358	Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 925-933.	5.5	30
359	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. <i>American Heart Journal</i> , 2021, 233, 141-148.	1.2	30
360	Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx. <i>JACC Basic To Translational Science</i> , 2021, 6, 485-496.	1.9	30

#	ARTICLE	IF	CITATIONS
361	Differential effect of β -blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. <i>Diabetic Medicine</i> , 2007, 24, 759-763.	1.2	29
362	Dysglycemia Predicts Cardiovascular and Kidney Disease in the Kidney Early Evaluation Program. <i>Journal of Clinical Hypertension</i> , 2010, 12, 51-58.	1.0	29
363	Treatment and Control of High Blood Pressure in Adults. <i>Cardiology Clinics</i> , 2010, 28, 609-622.	0.9	29
364	Effects of Dihydropyridine Calcium Antagonists on Albuminuria in Patients with Diabetes. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 274-279.	1.0	28
365	The Message for World Kidney Day 2009: Hypertension and Kidney Disease: A Marriage That Should Be Prevented. <i>Journal of Clinical Hypertension</i> , 2009, 11, 144-147.	1.0	28
366	Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study Equations: Prevalence of and Risk Factors for Diabetes Mellitus in CKD in the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2011, 57, S24-S31.	2.1	28
367	Baseline characteristics and enrichment results from the <sc>SONAR</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1829-1835.	2.2	28
368	Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 398-405.	2.2	28
369	Major Advancements in Slowing Diabetic Kidney Disease Progression: Focus on SGLT2 Inhibitors. <i>American Journal of Kidney Diseases</i> , 2019, 74, 573-575.	2.1	28
370	Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e012797.	1.6	28
371	β -Blocker use and diabetes symptom score: results from the GEMINI study. <i>Diabetes, Obesity and Metabolism</i> , 2007, 9, 408-417.	2.2	27
372	The message for World Kidney Day 2009: hypertension and kidney disease "a marriage that should be prevented. <i>Journal of Hypertension</i> , 2009, 27, 666-669.	0.3	27
373	Noninsulin glucose-lowering agents for the treatment of patients on dialysis. <i>Nature Reviews Nephrology</i> , 2013, 9, 147-153.	4.1	27
374	Design Considerations for Clinical Trials of Autonomic Modulation Therapies Targeting Hypertension and Heart Failure. <i>Hypertension</i> , 2015, 65, 5-15.	1.3	27
375	Intensive Hemodialysis and Potential Risks With Increasing Treatment. <i>American Journal of Kidney Diseases</i> , 2016, 68, S51-S58.	2.1	27
376	Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? Yes, They Should Be Relaxed! What's the Fuss?. <i>Diabetes Care</i> , 2016, 39, 1287-1291.	4.3	27
377	Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease. <i>Hypertension</i> , 2020, 76, 144-149.	1.3	27
378	How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?. <i>Current Hypertension Reports</i> , 2003, 5, 418-425.	1.5	26

#	ARTICLE	IF	CITATIONS
379	24-Hour Ambulatory Blood Pressure in the ACCOMPLISH Trial. <i>New England Journal of Medicine</i> , 2010, 363, 98-98.	13.9	26
380	Oral potassium supplement use and outcomes in chronic heart failure: A propensity-matched study. <i>International Journal of Cardiology</i> , 2010, 141, 167-174.	0.8	26
381	Importance of blood pressure control in left ventricular mass regression. <i>Journal of the American Society of Hypertension</i> , 2010, 4, 302-310.	2.3	26
382	Using an Established Telehealth Model to Train Urban Primary Care Providers on Hypertension Management. <i>Journal of Clinical Hypertension</i> , 2012, 14, 45-50.	1.0	26
383	Hypertension Management in Diabetic Kidney Disease. <i>Diabetes Spectrum</i> , 2015, 28, 175-180.	0.4	26
384	Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. <i>Journal of Hypertension</i> , 2016, 34, 788-797.	0.3	26
385	Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. <i>Journal of Clinical Hypertension</i> , 2016, 18, 299-307.	1.0	26
386	Predictors of renal and cardiovascular mortality in patients with non-insulin-dependent diabetes: A brief overview of microalbuminuria and insulin resistance. <i>Journal of Diabetes and Its Complications</i> , 1997, 11, 352-357.	1.2	25
387	Protecting renal function in the hypertensive patient: Clinical guidelines. <i>American Journal of Hypertension</i> , 2005, 18, 112-119.	1.0	25
388	Effects of angiotensin II receptor blockers on diabetic nephropathy. <i>Journal of Hypertension</i> , 2009, 27, S15-S21.	0.3	25
389	Sustainable Community-Based CKD Screening Methods Employed by the National Kidney Foundation's Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2011, 57, S4-S8.	2.1	25
390	Comparison of Benazepril Plus Amlodipine or Hydrochlorothiazide in High-Risk Patients With Hypertension and Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2013, 112, 255-259.	0.7	25
391	Differences in Dynamic Diurnal Blood Pressure Variability Between Japanese and American Treatment-Resistant Hypertensive Populations. <i>Circulation Journal</i> , 2017, 81, 1337-1345.	0.7	25
392	Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. <i>Journal of the National Medical Association</i> , 2006, 98, 618-26.	0.6	25
393	Chapter 23 Treatment of the diabetic patient: focus on cardiovascular and renal risk reduction. <i>Progress in Brain Research</i> , 2002, 139, 289-298.	0.9	24
394	Blood Pressure Control and Nephroprotection in Diabetes. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 431-438.	1.0	24
395	Obesity and Insulin Resistance As Risk Factors for Chronic Kidney Disease. <i>Journal of the Cardiometabolic Syndrome</i> , 2006, 1, 209-216.	1.7	24
396	The kidney and cardiovascular risk – Implications for management: A consensus statement from the European Society of Hypertension. <i>Blood Pressure</i> , 2007, 16, 72-79.	0.7	24

#	ARTICLE	IF	CITATIONS
397	Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 385-389.	1.5	24
398	Editorial Perspective. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial. <i>American Journal of Nephrology</i> , 2010, 31, 469-470.	1.4	24
399	The Role of Vasodilating β -Blockers in Patients with Hypertension and the Cardiometabolic Syndrome. <i>American Journal of Medicine</i> , 2010, 123, S21-S26.	0.6	24
400	Mineralocorticoid antagonists in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2017, 26, 50-55.	1.0	24
401	Role for β -blockers in the management of diabetic kidney disease. <i>American Journal of Hypertension</i> , 2003, 16, 7-12.	1.0	23
402	When Does New Onset Diabetes Resulting From Antihypertensive Therapy Increase Cardiovascular Risk. <i>Hypertension</i> , 2004, 43, 941-942.	1.3	23
403	Is proteinuria a plausible target of therapy?. <i>Current Hypertension Reports</i> , 2004, 6, 177-181.	1.5	23
404	Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. <i>American Journal of Hypertension</i> , 2004, 17, 590-596.	1.0	23
405	The role of calcium antagonists in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2004, 13, 155-161.	1.0	23
406	Effect of Combining Extended-Release Carvedilol and Lisinopril in Hypertension: Results of the COSMOS Study. <i>Journal of Clinical Hypertension</i> , 2010, 12, 678-686.	1.0	23
407	An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems. <i>Journal of the American Society of Hypertension</i> , 2017, 11, 81-91.	2.3	23
408	The Kidney in Hypertension. <i>Medical Clinics of North America</i> , 2017, 101, 207-217.	1.1	23
409	Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial. <i>Clinical Research in Cardiology</i> , 2021, 110, 1006-1019.	1.5	23
410	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108101.	1.2	23
411	Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-KD trial. <i>European Journal of Heart Failure</i> , 2022, 24, 996-1005.	2.9	23
412	Salt intake and reductions in arterial pressure and proteinuria is there a direct link?. <i>American Journal of Hypertension</i> , 1996, 9, S200-S206.	1.0	22
413	The Renin-Angiotensin System in Diabetic Nephropathy: The Endothelial Connection. <i>Mineral and Electrolyte Metabolism</i> , 1998, 24, 381-388.	1.1	22
414	Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease?. <i>Current Opinion in Nephrology and Hypertension</i> , 2009, 18, 386-391.	1.0	22

#	ARTICLE	IF	CITATIONS
415	Orthostatic Hypotension Associated With Baroreceptor Dysfunction: Treatment Approaches. <i>Journal of Clinical Hypertension</i> , 2014, 16, 141-148.	1.0	22
416	Effects of antihypertensive treatment in Asian populations: A meta-analysis of prospective randomized controlled studies (CARDiovascular protection group in Asia: CARNA). <i>Journal of the American Society of Hypertension</i> , 2014, 8, 103-116.	2.3	22
417	Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?. <i>Blood Purification</i> , 2016, 41, 139-143.	0.9	22
418	The role of combination antihypertensive therapy and the progression of renal disease hypertension Looking toward the next millennium. <i>American Journal of Hypertension</i> , 1998, 11, 158S-162S.	1.0	21
419	Does dietary salt increase the risk for progression of kidney disease?. <i>Current Hypertension Reports</i> , 2005, 7, 385-391.	1.5	21
420	Do the Metabolic Effects of ? Blockers Make Them Leading or Supporting Antihypertensive Agents in the Treatment of Hypertension?. <i>Journal of Clinical Hypertension</i> , 2006, 8, 351-356.	1.0	21
421	Level of Kidney Function Determines Cardiovascular Fate After Coronary Bypass Graft Surgery. <i>Circulation</i> , 2006, 113, 1046-1047.	1.6	21
422	Combination Therapy With Reninâ€Angiotensinâ€Aldosterone Receptor Blockers for Hypertension: How Far Have We Come?. <i>Journal of Clinical Hypertension</i> , 2008, 10, 146-152.	1.0	21
423	Lipid Disorders in Uremia and Dialysis. <i>Contributions To Nephrology</i> , 2012, 178, 100-105.	1.1	21
424	Baseline characteristics in the Bardoxolone methyl Evaluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal events (BEACON) trial. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2841-2850.	0.4	21
425	Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. <i>Hypertension</i> , 2016, 68, 606-613.	1.3	21
426	Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?. <i>Current Diabetes Reports</i> , 2016, 16, 24.	1.7	21
427	Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by <scp>SCAI</scp> and <scp>NKF</scp>. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 416-426.	0.7	21
428	The effects of calcium antagonists on renal hemodynamics, urinary protein excretion, and glomerular morphology in diabetic states.. <i>Journal of the American Society of Nephrology: JASN</i> , 1991, 2, S21.	3.0	21
429	Effect of Fixedâ€Dose ACEâ€Inhibitor/Calcium Channel Blocker Combination Therapy vs. ACEâ€Inhibitor Monotherapy on Arterial Compliance in Hypertensive Patients With Type 2 Diabetes. <i>Preventive Cardiology</i> , 2005, 8, 87-92.	1.1	20
430	Reversal of Diuretic-Associated Impaired Glucose Tolerance and New-Onset Diabetes: Results of the STAR-LET Study. <i>Journal of the Cardiometabolic Syndrome</i> , 2008, 3, 18-25.	1.7	20
431	Renal Hemodynamic Changes in Heart Failure. <i>Heart Failure Clinics</i> , 2008, 4, 411-423.	1.0	20
432	New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. <i>International Journal of Cardiology</i> , 2016, 216, 46-51.	0.8	20

#	ARTICLE	IF	CITATIONS
433	Does Evidence Support Renin-angiotensin System Blockade for Slowing Nephropathy Progression in Elderly Persons?. <i>Annals of Internal Medicine</i> , 2009, 150, 731.	2.0	20
434	Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. <i>Diabetes Care</i> , 2022, 45, e888-e897.	4.3	20
435	Choreoathetosis associated with lithium: case report and literature review. <i>American Journal of Psychiatry</i> , 1983, 140, 1621-1622.	4.0	19
436	The renal, forearm, and hormonal responses to standing in the presence and absence of propranolol.. <i>Circulation</i> , 1986, 74, 1061-1065.	1.6	19
437	Evaluation and Treatment of Patients With Systemic Hypertension. <i>Circulation</i> , 2002, 105, 2458-2461.	1.6	19
438	The rationale and design of the Glycemic Effects in Diabetes Mellitus. <i>Journal of Diabetes and Its Complications</i> , 2005, 19, 74-79.	1.2	19
439	A Propensity-Matched Study of Hypertension and Increased Stroke-Related Hospitalization in Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2008, 101, 1772-1776.	0.7	19
440	Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 757-769.	2.2	19
441	Racial Differences in Kidney Function Among Individuals With Obesity and Metabolic Syndrome: Results From the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2010, 55, S4-S14.	2.1	19
442	Management of Hypertension in the Elderly Population. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2012, 67, 1343-1351.	1.7	19
443	Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2017, 26, 368-374.	1.0	19
444	Are All Patients With Type 1 Diabetes Destined for Dialysis if They Live Long Enough? Probably Not. <i>Diabetes Care</i> , 2018, 41, 389-390.	4.3	19
445	Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e009114.	1.6	19
446	The Use of Antisense Oligonucleotides to Establish Autocrine Angiotensin Growth Effects in Human Neuroblastoma and Mesangial Cells. <i>Antisense Research and Development</i> , 1992, 2, 199-210.	3.3	18
447	Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. <i>American Journal of Hypertension</i> , 2003, 16, 460-466.	1.0	18
448	Proteinuria. <i>Hypertension</i> , 2005, 46, 473-474.	1.3	18
449	Comparative Antihypertensive Efficacy of Angiotensin Receptor Blocker-Based Treatment in African-American and White Patients. <i>Journal of Clinical Hypertension</i> , 2005, 7, 587-597.	1.0	18
450	Lowering Blood Pressure With β -Blockers in Combination With Other Renin-angiotensin System Blockers in Patients With Hypertension and Type 2 Diabetes: Results From the GEMINI Trial. <i>Journal of Clinical Hypertension</i> , 2007, 9, 842-849.	1.0	18

#	ARTICLE	IF	CITATIONS
451	Demographic Analyses of the Effects of Carvedilol vs Metoprolol on Glycemic Control and Insulin Sensitivity in Patients With Type 2 Diabetes and Hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilolâ€Metoprolol Comparison in Hypertensives (GEMINI) Study. <i>Journal of the Cardiometabolic Syndrome</i> , 2008, 3, 211-217.	1.7	18
452	Predictors of Hypertension Control in a Diverse General Cardiology Practice. <i>Journal of Clinical Hypertension</i> , 2010, 12, 570-577.	1.0	18
453	Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 181-186.	2.2	18
454	Controversies in the 2017 ACC/AHA Hypertension Guidelines: Who Can Be Eligible for Treatments Under the New Guidelines?â€• An Asian Perspective â€•. <i>Circulation Journal</i> , 2019, 83, 504-510.	0.7	18
455	The Appropriate Blood Pressure Control in Diabetes (ABCD) Trial. <i>Journal of Human Hypertension</i> , 1998, 12, 653-655.	1.0	17
456	Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes. <i>Current Hypertension Reports</i> , 2002, 4, 185-190.	1.5	17
457	Angiotensin Receptor Blockade and Arterial Compliance in Chronic Kidney Disease: A Pilot Study. <i>American Journal of Nephrology</i> , 2005, 25, 393-399.	1.4	17
458	Prevention of Microalbuminuria in Patients With Type 2 Diabetes: What Do We Know?. <i>Journal of Clinical Hypertension</i> , 2010, 12, 422-430.	1.0	17
459	Blood Pressure Targets for Patients with Diabetes or Kidney Disease. <i>Current Hypertension Reports</i> , 2011, 13, 452-455.	1.5	17
460	Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program. <i>CardioRenal Medicine</i> , 2011, 1, 45-52.	0.7	17
461	Single-Pill Combination of Telmisartan/Amlodipine Versus Amlodipine Monotherapy in Diabetic Hypertensive Patients: An 8-Week Randomized, Parallel-Group, Double-Blind Trial. <i>Clinical Therapeutics</i> , 2012, 34, 537-551.	1.1	17
462	Endothelin Antagonism and Hypertension: An Evolving Target. <i>Seminars in Nephrology</i> , 2015, 35, 168-175.	0.6	17
463	The promise of renal denervation. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, 498-500.	0.6	17
464	The Future of Clinical Trials in Chronic Renal Disease: Outcome of an NIH/FDA/Physician Specialist Conference. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 815-825.	1.0	16
465	Hypertension in patients with diabetes. <i>Postgraduate Medicine</i> , 2000, 107, 53-64.	0.9	16
466	Angiotensin-converting enzyme inhibition to enhance vascular health?clinical and research models. <i>American Journal of Hypertension</i> , 2001, 14, S264-S269.	1.0	16
467	Insulin Resistance, Hyperinsulinemia, and Hypertension: An Epidemiologic Approach. <i>Journal of the Cardiometabolic Syndrome</i> , 2006, 1, 334-344.	1.7	16
468	Calcium antagonists: Do they equally protect against kidney injury?. <i>Kidney International</i> , 2008, 73, 795-796.	2.6	16

#	ARTICLE	IF	CITATIONS
469	Influence of microalbuminuria in achieving blood pressure goals. <i>Current Opinion in Nephrology and Hypertension</i> , 2008, 17, 457-463.	1.0	16
470	Effects of Naproxcinod on Blood Pressure in Patients With Osteoarthritis. <i>American Journal of Cardiology</i> , 2011, 107, 1338-1345.	0.7	16
471	Pros and Cons of Aggressive Blood Pressure Lowering in Patients with Type 2 Diabetes. <i>Current Vascular Pharmacology</i> , 2012, 10, 156-161.	0.8	16
472	The Future of Renal Denervation in Resistant Hypertension. <i>Current Hypertension Reports</i> , 2014, 16, 494.	1.5	16
473	Hypertension and new treatment approaches targeting the sympathetic nervous system. <i>Current Opinion in Pharmacology</i> , 2015, 21, 20-24.	1.7	16
474	Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 69-76.	2.2	16
475	Red cell distribution width in patients with diabetes and myocardial infarction: An analysis from the <sc>EXAMINE</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1580-1587.	2.2	16
476	Should nephrologists use beta-blockers? A perspective. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 701-702.	0.4	15
477	Comparison of Dual RAAS Blockade and Higher-Dose RAAS Inhibition on Nephropathy Progression. <i>Postgraduate Medicine</i> , 2008, 120, 33-42.	0.9	15
478	Treatment of hypertension in patients with diabetes—an update. <i>Journal of the American Society of Hypertension</i> , 2009, 3, 150-155.	2.3	15
479	Effects of Nebivolol on Aortic Compliance in Patients With Diabetes and Maximal Renin Angiotensin System Blockade: The <sc>EFFORT</sc> Study. <i>Journal of Clinical Hypertension</i> , 2013, 15, 473-479.	1.0	15
480	Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 845-854.	2.3	15
481	Association of Arterial Stiffness With Kidney Function Among Adults Without Chronic Kidney Disease. <i>American Journal of Hypertension</i> , 2020, 33, 1003-1010.	1.0	15
482	Major adverse renal events (MARE): a proposal to unify renal endpoints. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 491-497.	0.4	15
483	Renal effects of oral prostaglandin supplementation after ibuprofen in diabetic subjects: a double-blind, placebo-controlled, multicenter trial. <i>Journal of the American Society of Nephrology: JASN</i> , 1995, 5, 1684-1688.	3.0	15
484	Implications of Albuminuria on Kidney Disease Progression. <i>Journal of Clinical Hypertension</i> , 2004, 6, 18-22.	1.0	14
485	The Message for World Kidney Day 2009. <i>American Journal of Nephrology</i> , 2009, 30, 95-98.	1.4	14
486	The current state of RAAS blockade in the treatment of hypertension and proteinuria. <i>Current Cardiology Reports</i> , 2009, 11, 436-442.	1.3	14

#	ARTICLE	IF	CITATIONS
487	Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome. <i>Clinical Research in Cardiology</i> , 2021, 110, 1612-1624.	1.5	14
488	Serum Creatinine vs. Albuminuria as Biomarkers for the Estimation of Cardiovascular Risk. <i>Current Vascular Pharmacology</i> , 2010, 8, 604-611.	0.8	14
489	Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials. <i>JAMA Cardiology</i> , 2022, 7, 549.	3.0	14
490	Efficacy and Safety of Fixed Combinations of Irbesartan/Hydrochlorothiazide in Older vs Younger Patients With Hypertension Uncontrolled With Monotherapy. <i>The American Journal of Geriatric Cardiology</i> , 2008, 17, 27-36.	0.7	13
491	Comparative Efficacy of Two Different β -Blockers on 24-Hour Blood Pressure Control. <i>Journal of Clinical Hypertension</i> , 2008, 10, 112-118.	1.0	13
492	The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. <i>Journal of the American Society of Hypertension</i> , 2009, 3, 80-83.	2.3	13
493	Dual RAAS blockade is desirable in kidney disease: Con. <i>Kidney International</i> , 2010, 78, 546-549.	2.6	13
494	Renal Denervation and Left Ventricular Mass Regression. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1924-1925.	1.2	13
495	New insights into cardiovascular risk factors and outcomes. <i>Nature Reviews Nephrology</i> , 2015, 11, 70-72.	4.1	13
496	The Management of Hypertension in 2018: What Should the Targets Be?. <i>Current Hypertension Reports</i> , 2019, 21, 41.	1.5	13
497	Barriers to guideline mandated renin-angiotensin inhibitor use: focus on hyperkalaemia. <i>European Heart Journal Supplements</i> , 2019, 21, A20-A27.	0.0	13
498	Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease. <i>Postgraduate Medicine</i> , 2023, 135, 224-233.	0.9	13
499	Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 372-383.	0.4	13
500	Current Issues in Treating the Hypertensive Patient with Diabetes: Focus on Diabetic Nephropathy. <i>Annals of Pharmacotherapy</i> , 1996, 30, 791-801.	0.9	12
501	ImmunoDip [®] : An Improved Screening Method for Microalbuminuria. <i>American Journal of Nephrology</i> , 2004, 24, 284-288.	1.4	12
502	The JNC 7 Approach Compared to Conventional Treatment in Diabetic Patients With Hypertension: A Double-Blind Trial of Initial Monotherapy vs. Combination Therapy. <i>Journal of Clinical Hypertension</i> , 2004, 6, 437-442.	1.0	12
503	The Role of Hyperglycaemia and the Hypercoagulable State in the Pathogenesis of Cardiovascular Events in Diabetes Mellitus: Implications for Hypertension Management. <i>Current Pharmaceutical Design</i> , 2006, 12, 1567-1579.	0.9	12
504	The message for World Kidney Day 2009: hypertension and kidney disease a marriage that should be prevented. <i>Journal of Human Hypertension</i> , 2009, 23, 222-225.	1.0	12

#	ARTICLE	IF	CITATIONS
505	The Role of Nitric Oxide in Improving Endothelial Function and Cardiovascular Health: Focus on Nebivolol. <i>American Journal of Medicine</i> , 2010, 123, S2-S8.	0.6	12
506	Treatment of hypertension in patients with diabetes—an update. <i>Journal of the American Society of Hypertension</i> , 2010, 4, 62-67.	2.3	12
507	Timing and Efficacy of Alternative Methods of Sympathetic Blockade. <i>Current Hypertension Reports</i> , 2012, 14, 455-461.	1.5	12
508	Effects of Vascular Endothelial Growth Factor Signaling Inhibition on Human Erythropoiesis. <i>Oncologist</i> , 2013, 18, 965-970.	1.9	12
509	Sympathetic Activation in Resistant Hypertension: Theory and Therapy. <i>Seminars in Nephrology</i> , 2014, 34, 550-559.	0.6	12
510	Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). <i>American Journal of Cardiology</i> , 2019, 123, 382-391.	0.7	12
511	Intersection Between Chronic Kidney Disease and Cardiovascular Disease. <i>Current Cardiology Reports</i> , 2021, 23, 117.	1.3	12
512	Telmisartan in incipient and overt diabetic renal disease. <i>Journal of Nephrology</i> , 2011, 24, 263-273.	0.9	12
513	Microalbuminuria and progressive renal disease. <i>Journal of Human Hypertension</i> , 1994, 8, 809-17.	1.0	12
514	Comparison of Telmisartan vs. Valsartan in the Treatment of Mild to Moderate Hypertension Using Ambulatory Blood Pressure Monitoring. <i>Journal of Clinical Hypertension</i> , 2000, 5, 26-31.	1.0	11
515	Inclusion of albuminuria in hypertension and heart guidelines. <i>Kidney International</i> , 2004, 66, S124-S125.	2.6	11
516	Monitoring and Managing Urinary Albumin Excretion: Practical Advice for Primary Care Clinicians. <i>Postgraduate Medicine</i> , 2009, 121, 51-60.	0.9	11
517	The Association between Parathyroid Hormone Levels and the Cardiorenal Metabolic Syndrome in Non-Diabetic Chronic Kidney Disease. <i>CardioRenal Medicine</i> , 2011, 1, 123-130.	0.7	11
518	Both Chronic Kidney Disease and Nocturnal Blood Pressure Associate with Strokes in the Elderly. <i>American Journal of Nephrology</i> , 2013, 38, 195-203.	1.4	11
519	Sorafenib Dose Escalation Is Not Uniformly Associated With Blood Pressure Elevations in Normotensive Patients With Advanced Malignancies. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 27-35.	2.3	11
520	Efficacy and safety of perindopril arginine + amlodipine in hypertension. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 266-274.	2.3	11
521	Renal Denervation After SYMPPLICITY HTN-3: Where Do We Go?. <i>Canadian Journal of Cardiology</i> , 2015, 31, 642-648.	0.8	11
522	Spirolactone for resistant hypertension—“hard to resist?”. <i>Lancet, The</i> , 2015, 386, 2032-2034.	6.3	11

#	ARTICLE	IF	CITATIONS
523	Renal Targeted Therapies of Antihypertensive and Cardiovascular Drugs for Patients With Stages 3 Through 5d Kidney Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 450-458.	2.3	11
524	Creatinine Bump Following Antihypertensive Therapy. <i>Hypertension</i> , 2018, 72, 1274-1276.	1.3	11
525	Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 798-806.	2.2	11
526	The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1824-1832.	2.2	11
527	Antihypertensive therapy and the risk of new-onset diabetes. <i>Diabetes Care</i> , 2006, 29, 1167-9.	4.3	11
528	Kidney Failure and Cardiovascular Disease. <i>Circulation</i> , 2003, 108, e114-5.	1.6	10
529	Diabetes and Chronic Kidney Disease: Tragedy and Challenge. <i>Blood Purification</i> , 2004, 22, 130-135.	0.9	10
530	Changes in Kidney Function Following Heart Failure Treatment: Focus on Renin-Angiotensin System Blockade. <i>Heart Failure Clinics</i> , 2008, 4, 425-438.	1.0	10
531	Lower Blood Pressure Goals for Cardiovascular and Renal Risk Reduction: Are They Defensible?. <i>Journal of Clinical Hypertension</i> , 2009, 11, 345-347.	1.0	10
532	Glycemic control and cardiovascular disease in chronic kidney disease. <i>Current Diabetes Reports</i> , 2009, 9, 243-248.	1.7	10
533	Endothelin Antagonism in Patients with Resistant Hypertension and Hypertension Nephropathy. <i>Contributions To Nephrology</i> , 2011, 172, 223-234.	1.1	10
534	Chronic kidney disease: a coronary heart disease equivalent?. <i>Lancet, The</i> , 2012, 380, 783-785.	6.3	10
535	Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. <i>Blood Pressure Monitoring</i> , 2014, 19, 90-97.	0.4	10
536	Relationship Between Obesity, Hypertension, and Aldosterone Production in Postmenopausal African American Women: A Pilot Study. <i>Journal of Clinical Hypertension</i> , 2016, 18, 1216-1221.	1.0	10
537	Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. <i>Journal of Clinical Hypertension</i> , 2018, 20, 694-702.	1.0	10
538	Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes. <i>Diabetes Care</i> , 2018, 41, 662-663.	4.3	10
539	Has the Sun Set on Nighttime Dosing in Uncomplicated Hypertension?. <i>Hypertension</i> , 2018, 72, 836-838.	1.3	10
540	Assessing Wide Pulse Pressure Hypertension. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2856-2858.	1.2	10

#	ARTICLE	IF	CITATIONS
541	Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 561-568.	2.2	10
542	An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1017-1023.	1.9	10
543	Untreated Hypertension and Subsequent Incidence of Colorectal Cancer: Analysis of a Nationwide Epidemiological Database. <i>Journal of the American Heart Association</i> , 2021, 10, e022479.	1.6	10
544	Hypertension in Diabetic Patients: An Update of Interventional Studies to Preserve Renal Function. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 73-80.	1.0	9
545	Microalbuminuria in diabetes: Focus on cardiovascular and renal risk reduction. <i>Current Diabetes Reports</i> , 2002, 2, 258-262.	1.7	9
546	Hypertension Treatment Guidelines: Practical Implications. <i>Seminars in Nephrology</i> , 2005, 25, 198-209.	0.6	9
547	Cardiovascular Risk Factors in Hypertension: Rationale and Design of Studies to Investigate the Effects of Controlled-Release Carvedilol on Regression of Left Ventricular Hypertrophy and Lipid Profile. <i>American Journal of Cardiology</i> , 2006, 98, 46-52.	0.7	9
548	The Diabetes Subgroup Baseline Characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) Trial. <i>Journal of the Cardiometabolic Syndrome</i> , 2008, 3, 229-233.	1.7	9
549	Hypertension Goals in Advanced-Stage Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, S92-S94.	2.2	9
550	World Kidney Day 2009: Hypertension and Kidney Disease Is a Marriage That Should Be Prevented. <i>American Journal of Kidney Diseases</i> , 2009, 53, 373-376.	2.1	9
551	Complete Renin-Angiotensin-Aldosterone System (RAAS) Blockade in High-Risk Patients. <i>Hypertension</i> , 2013, 62, 444-449.	1.3	9
552	The Future of Interventional Management of Hypertension: Threats and Opportunities. <i>Current Vascular Pharmacology</i> , 2014, 12, 69-76.	0.8	9
553	Racial impact of diurnal variations in blood pressure on cardiovascular events in chronic kidney disease. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 299-306.	2.3	9
554	Early and Chronic Dipeptidyl Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	9
555	Evolution of Patiromer Use: a Review. <i>Current Cardiology Reports</i> , 2020, 22, 94.	1.3	9
556	Time in Therapeutic Range. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1300-1301.	1.2	9
557	Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2900-2911.	3.0	9
558	Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDESCENCE Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 361-373.	2.2	9

#	ARTICLE	IF	CITATIONS
559	Renal dysfunction resulting from NSAIDs. <i>American Family Physician</i> , 1989, 40, 199-204.	0.1	9
560	Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1197-1205.	2.2	9
561	Renal Effects of Antihypertensive Medications: An Overview. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 392-399.	1.0	8
562	Blood pressure, antihypertensive therapy and risk for renal injury in African-Americans. <i>Current Opinion in Nephrology and Hypertension</i> , 2003, 12, 79-84.	1.0	8
563	The message for World Kidney Day 2009: Hypertension and kidney disease: a marriage that should be prevented. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 695-697.	0.4	8
564	National Kidney Foundation's Kidney Early Evaluation Program (KEEP) Annual Data Report 2010: Executive Summary. <i>American Journal of Kidney Diseases</i> , 2011, 57, S1-S3.	2.1	8
565	Masked and Nocturnal Hypertension in the ARTS-DN ABPM Sub-Study with Finerenone. <i>Journal of the American Society of Hypertension</i> , 2016, 10, e7.	2.3	8
566	Prior Medications and the Cardiovascular Benefits From Combination Angiotensinâ€Converting Enzyme Inhibition Plus Calcium Channel Blockade Among Highâ€Risk Hypertensive Patients. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	8
567	Blood Pressure Control and Cardiovascular/Renal Outcomes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 175-184.	1.2	8
568	A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes. <i>Diabetes Care</i> , 2021, 44, 8-10.	4.3	8
569	Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial. <i>American Journal of Nephrology</i> , 2021, 52, 969-976.	1.4	8
570	Kidney function assessment and endpoint ascertainment in clinical trials. <i>European Heart Journal</i> , 2022, 43, 1379-1400.	1.0	8
571	Drug dosing in patients with renal insufficiency. <i>Postgraduate Medicine</i> , 1993, 94, 153-164.	0.9	7
572	New therapies in diabetes â€“ thiazolidinediones. <i>Expert Opinion on Emerging Drugs</i> , 2000, 5, 441-456.	1.1	7
573	Pathogenesis and clinical physiology of hypertension. <i>Cardiology Clinics</i> , 2002, 20, 195-206.	0.9	7
574	Î²-Blockers in the Treatment of Hypertension: New Data, New Directions. <i>Journal of Clinical Hypertension</i> , 2008, 10, 234-238.	1.0	7
575	Rationale for Establishing a Mechanism to Increase Reimbursement to Hypertension Specialists. <i>Journal of Clinical Hypertension</i> , 2013, 15, 397-403.	1.0	7
576	Early Patterns of Blood Pressure Change and Future Coronary Atherosclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 471.	3.8	7

#	ARTICLE	IF	CITATIONS
577	<i>Diabetes Care</i>: â€œTaking It to the Limit One More Timeâ€• Diabetes Care, 2017, 40, 3-6.	4.3	7
578	Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease. Circulation, 2018, 137, 130-133.	1.6	7
579	Ambulatory Blood Pressure Monitoring. JAMA - Journal of the American Medical Association, 2018, 320, 1807.	3.8	7
580	Similarities and Differences Between the ACC/AHA and ESH/ESC Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Circulation Research, 2019, 124, 969-971.	2.0	7
581	Heart Failure and Changes in Kidney Function. Heart Failure Clinics, 2019, 15, 455-461.	1.0	7
582	Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes?. Lancet Diabetes and Endocrinology,the, 2020, 8, 553-555.	5.5	7
583	Response by Filippatos et al to Letter Regarding Article, â€œFinerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetesâ€•, Circulation, 2021, 144, e202-e203.	1.6	7
584	Generalizability of FIGAROâ€™DKD and FIDELIOâ€™DKD Trial Criteria to the US Population Eligible for Finerenone. Journal of the American Heart Association, 2022, 11, e025079.	1.6	7
585	Lithium prophylaxis and the kidney. Journal of Affective Disorders, 1981, 3, 37-42.	2.0	6
586	Treatment of stage I hypertension and development of renal dysfunction. Journal of Human Hypertension, 2001, 15, 81-84.	1.0	6
587	Optimal treatment of hypertension in African Americans. Postgraduate Medicine, 2002, 112, 73-84.	0.9	6
588	Protein Kinase C-Î² Inhibition: A Promise Not Yet Fulfilled. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 619-620.	2.2	6
589	Improving Blood Pressure Control Rates: Is There More We Can Do?. Journal of Clinical Hypertension, 2007, 9, 134-142.	1.0	6
590	Assessing Blood Pressure Control in Dialysis Patients. Hypertension, 2009, 53, 448-449.	1.3	6
591	Are Renin-Angiotensin-Aldosterone System Blockers Distinguishable Based on Cardiovascular and Renal Outcomes in Nephropathy?. Postgraduate Medicine, 2009, 121, 77-88.	0.9	6
592	Fixed-dose combination and chronic kidney disease progression: which is the best?. Current Opinion in Nephrology and Hypertension, 2010, 19, 450-455.	1.0	6
593	Cardiovascular risk modification in participants with coronary disease screened by the Kidney Early Evaluation Program. Internal Medicine Journal, 2010, 40, 833-841.	0.5	6
594	Use of a Single Target Blood Pressure Level in Type 2 Diabetes Mellitus for All Cardiovascular Risk Reduction. Archives of Internal Medicine, 2012, 172, 1304.	4.3	6

#	ARTICLE	IF	CITATIONS
595	New insights from risk factors to treatment implications. <i>Nature Reviews Cardiology</i> , 2012, 9, 75-77.	6.1	6
596	Metformin nephrotoxicity insights: Will they change clinical management? <i>Hypertension</i> , 2014, 6, 111-112.	0.8	6
597	A clinician's perspective of the role of renal sympathetic nerves in hypertension. <i>Frontiers in Physiology</i> , 2015, 6, 75.	1.3	6
598	Update on Blood Pressure Goals in Diabetes Mellitus. <i>Current Cardiology Reports</i> , 2015, 17, 37.	1.3	6
599	New Agents for Hyperkalemia. <i>New England Journal of Medicine</i> , 2015, 372, 1569-1572.	13.9	6
600	Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. <i>American Heart Journal</i> , 2016, 175, 18-27.	1.2	6
601	Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African American patients with hypertension. <i>Journal of Clinical Hypertension</i> , 2017, 19, 695-701.	1.0	6
602	Consequences of Overinterpreting Serum Creatinine Increases when Achieving BP Reduction. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 9-10.	2.2	6
603	Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. <i>American Journal of Cardiology</i> , 2018, 122, 1496-1505.	0.7	6
604	Improved Sleep Quality Improves Blood Pressure Control among Patients with Chronic Kidney Disease: A Pilot Study. <i>American Journal of Nephrology</i> , 2020, 51, 249-254.	1.4	6
605	The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1652-1659.	2.2	6
606	Disopyramide-associated liver dysfunction. <i>Mayo Clinic Proceedings</i> , 1983, 58, 265-7.	1.4	6
607	Cost-effectiveness of losartan in diabetic nephropathy: a Greek perspective. <i>Journal of Nephrology</i> , 2007, 20, 703-15.	0.9	6
608	Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists. <i>Current Diabetes Reports</i> , 2022, 22, 213.	1.7	6
609	Evolution of Drugs That Preserve Renal Function. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 978-989.	1.0	5
610	Treatment of hypertension in patients with renal disease. <i>Cardiovascular Drugs and Therapy</i> , 2002, 16, 503-510.	1.3	5
611	Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. <i>Journal of Human Hypertension</i> , 2005, 19, 139-144.	1.0	5
612	Preventing Hypertensive Kidney Disease: The Critical Role of Combination Therapy. <i>American Journal of Hypertension</i> , 2005, 18, 93-94.	1.0	5

#	ARTICLE	IF	CITATIONS
613	Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial. <i>Journal of Human Hypertension</i> , 2006, 20, 693-700.	1.0	5
614	The Cardiometabolic Syndrome and Calcium Channel Blocker Combination Drugs. <i>Journal of the Cardiometabolic Syndrome</i> , 2007, 2, 207-212.	1.7	5
615	Trials That Matter: The Effect of a Fixed-Dose Combination of an Angiotensin-Converting Enzyme Inhibitor and a Diuretic on the Complications of Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2008, 148, 400.	2.0	5
616	CON: Blood Pressure Treatment Goal for Patients With Diabetes Should Be $\leq 130/80\text{ mm Hg}$. <i>Journal of Clinical Hypertension</i> , 2011, 13, 263-265.	1.0	5
617	Approaches for targeting blood pressure control in sleep disorders. <i>Current Opinion in Nephrology and Hypertension</i> , 2012, 21, 469-474.	1.0	5
618	The OSCAR for cardiovascular disease prevention in chronic kidney disease goes to blood pressure control. <i>Kidney International</i> , 2013, 83, 20-22.	2.6	5
619	Status of Diabetes Care: "It Just Doesn't Get Any Better . . . or Does It?" <i>Diabetes Care</i> , 2014, 37, 1782-1785.	1.5	5
620	The Contribution of the ACCOMPLISH Trial to the Treatment of Stage 2 Hypertension. <i>Current Hypertension Reports</i> , 2014, 16, 419.	1.5	5
621	Status of Diabetes Care: New Challenges, New Concepts, New Measures" Focusing on the Future!. <i>Diabetes Care</i> , 2015, 38, 1177-1180.	4.3	5
622	SGLT2 inhibitors might halt progression of diabetic nephropathy. <i>Nature Reviews Nephrology</i> , 2016, 12, 583-584.	4.1	5
623	Results of ACCORDIAN in ACCORD with lower blood pressure begetting lower mortality in patients with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1335-1336.	2.2	5
624	Perspective on the New Blood-Pressure Guidelines. <i>European Heart Journal</i> , 2018, 39, 3008-3009.	1.0	5
625	Renal denervation: one step backwards, three steps forward. <i>Nature Reviews Nephrology</i> , 2018, 14, 602-604.	4.1	5
626	U.S. Prevalence of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 Inhibitor Therapy. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2907-2910.	1.2	5
627	Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1631-1638.	2.3	5
628	Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial. <i>Cardiovascular Diabetology</i> , 2021, 20, 187.	2.7	5
629	Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design. <i>American Journal of Nephrology</i> , 2022, 53, 50-58.	1.4	5
630	The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. <i>Diabetes and Metabolism</i> , 2022, 48, 101331.	1.4	5

#	ARTICLE	IF	CITATIONS
631	The use of clonidine for management of opiate abstinence in a chronic pain patient. Mayo Clinic Proceedings, 1982, 57, 657-60.	1.4	5
632	The Effects of Enalapril on Urinary Protein Excretion in Patients with Idiopathic Membranous Nephropathy. Journal of Clinical Pharmacology, 1990, 30, 155-158.	1.0	4
633	Calcium Antagonism Abolishes the Antipressor Action of Vasopressin (V1) Receptor Antagonism. American Journal of Hypertension, 1997, 10, 1153-1158.	1.0	4
634	Who Should Be Treated With Combination Therapy as Initial Treatment for Hypertension?. Journal of Clinical Hypertension, 2003, 5, 21-28.	1.0	4
635	The evolution of treatment guidelines for diabetic nephropathy. Postgraduate Medicine, 2003, 113, 35-50.	0.9	4
636	Clinical Implications of Blockade of the Renin-Angiotensin System in Management of Hypertension. , 2004, 143, 105-116.		4
637	Are β_2 Blockers Passé for the Treatment of Hypertension?. Journal of Clinical Hypertension, 2006, 8, 239-240.	1.0	4
638	ACE Inhibitors and ARBs: Are They Better Than Other Agents to Slow Nephropathy Progression?. Journal of Clinical Hypertension, 2007, 9, 413-415.	1.0	4
639	The Editor's Roundtable: Revisiting the Role of Beta Blockers in Hypertension. American Journal of Cardiology, 2007, 100, 253-267.	0.7	4
640	Optimal Blood Pressure for a Patient with Type 2 Diabetes Mellitus: Insight from the ACCORD Study. Current Hypertension Reports, 2010, 12, 313-315.	1.5	4
641	The United Nations High Level Meeting Addresses Noncommunicable Diseases, But Where Is Hypertension?. Journal of Clinical Hypertension, 2011, 13, 787-790.	1.0	4
642	Do fibrates truly preserve kidney function?. Nature Reviews Endocrinology, 2011, 7, 130-131.	4.3	4
643	Predictors of systolic BP \leq 140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study. Blood Pressure, 2012, 21, 82-87.	0.7	4
644	Indications for renal denervation: a balanced approach?. Nature Reviews Cardiology, 2013, 10, 434-436.	6.1	4
645	Renal Denervation for Resistant Hypertension and Beyond. Advances in Chronic Kidney Disease, 2015, 22, 133-139.	0.6	4
646	Hydrochlorothiazide as the Diuretic of Choice for Hypertension. Journal of the American College of Cardiology, 2016, 67, 390-391.	1.2	4
647	Finerenone for Albuminuria in Patients With Diabetic Nephropathy—Reply. JAMA - Journal of the American Medical Association, 2016, 315, 306.	3.8	4
648	Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status. Journal of Clinical Hypertension, 2017, 19, 1309-1318.	1.0	4

#	ARTICLE	IF	CITATIONS
649	A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. <i>Journal of Hypertension</i> , 2018, 36, 947-956.	0.3	4
650	Update on reducing the development of diabetic kidney disease and cardiovascular death in diabetes. <i>Kidney International Supplements</i> , 2018, 8, 1.	4.6	4
651	Big Topics for Diabetes Care in 2018: Clinical Guidelines, Costs of Diabetes, and Information Technology. <i>Diabetes Care</i> , 2018, 41, 1327-1329.	4.3	4
652	Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus. <i>American Heart Journal</i> , 2020, 229, 40-51.	1.2	4
653	How to Manage Hypertension in People With Diabetes. <i>American Journal of Hypertension</i> , 2020, 33, 935-943.	1.0	4
654	A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial. <i>Kidney360</i> , 2021, 2, 1240-1250.	0.9	4
655	Efficacy of baroreflex activation therapy for the treatment of resistant hypertension. <i>EuroIntervention</i> , 2013, 9, R136-R139.	1.4	4
656	Risk for renal injury in diabetic hypertensive patients. <i>Postgraduate Medicine</i> , 1992, 91, 77-84.	0.9	3
657	Is the level of arterial pressure reduction important for preservation of renal function. <i>Nephrology Dialysis Transplantation</i> , 1996, 11, 2383-2384.	0.4	3
658	Are antihypertensive drugs used to maximally reduce cardiovascular risk in dialysis patients?. <i>American Journal of Kidney Diseases</i> , 2003, 42, 1301-1304.	2.1	3
659	Proteinuria and Blood Pressure Reduction:. <i>Current Hypertension Reports</i> , 2005, 7, 357-358.	1.5	3
660	Evaluating the Cardiovascular Effects of the Thiazolidinediones and Their Place in the Management of Type 2 Diabetes in Relation to the Metabolic Syndrome. <i>Metabolic Syndrome and Related Disorders</i> , 2005, 3, 147-173.	0.5	3
661	An Effectiveness Study Comparing Algorithm-Based Antihypertensive Therapy With Previous Treatments Using Conventional and Ambulatory Blood Pressure Measurements. <i>Journal of Clinical Hypertension</i> , 2006, 8, 241-252.	1.0	3
662	Dual Therapy in Hypertensive Patients with Coronary Artery Disease: The Role of Calcium Channel Blockers and ??-Blockers. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 25-29.	1.0	3
663	Newer Combination Therapies in the Management of Hypertension: An Update. <i>Journal of Clinical Hypertension</i> , 2008, 10, 398-405.	1.0	3
664	Blood Pressure Control in the Patient With Difficult-to-Control Hypertension: Which Agent for Which Patient?. <i>Preventive Cardiology</i> , 2008, 11, 42-49.	1.1	3
665	Hypertension and its Management in the Elderly. <i>Seminars in Nephrology</i> , 2009, 29, 604-609.	0.6	3
666	Hypertension Following Kidney Injury. <i>Journal of Clinical Hypertension</i> , 2010, 12, 727-730.	1.0	3

#	ARTICLE	IF	CITATIONS
667	Masked hypertension: a risk factor in children with CKD. <i>Nature Reviews Nephrology</i> , 2010, 6, 132-134.	4.1	3
668	Blood pressure target for renoprotection in children. <i>Nature Reviews Nephrology</i> , 2010, 6, 67-68.	4.1	3
669	Role of Ambulatory Blood Pressure Monitoring in Hypertension and Diabetes. <i>Current Hypertension Reports</i> , 2013, 15, 137-142.	1.5	3
670	Efficacy and Safety of Canagliflozin (CANA) in Subjects with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) Over 52 Weeks. <i>Canadian Journal of Diabetes</i> , 2013, 37, S27.	0.4	3
671	Optimal blood pressure for kidney diseaseâ€”lower is not better. <i>Nature Reviews Nephrology</i> , 2013, 9, 634-635.	4.1	3
672	CaseBook Challenges: Managing Gout, Hyperuricemia and Comorbiditiesâ€”Dialogue with the Experts. <i>American Journal of Medicine</i> , 2014, 127, S1.	0.6	3
673	Renin inhibition in patients with chronic kidney disease: Is it conclusively non-indicated?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2014, 15, 97-98.	1.0	3
674	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 65, 959-960.	1.2	3
675	Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. <i>Atherosclerosis</i> , 2015, 243, 553-559.	0.4	3
676	Current Status of Renal Denervation in Hypertension. <i>Current Cardiology Reports</i> , 2016, 18, 107.	1.3	3
677	New Onset Hypertension Linked to Generic Cyclosporine Substitution in Post-Renal Transplant Patient. <i>American Journal of Nephrology</i> , 2016, 44, 219-223.	1.4	3
678	Catheter-Based Renal Denervation for Resistant Hypertension: Will It Ever Be Ready for â€œPrime Timeâ€?. <i>American Journal of Hypertension</i> , 2017, 30, 841-846.	1.0	3
679	Renal Denervation: a Field in Flux. <i>Current Hypertension Reports</i> , 2016, 18, 56.	1.5	3
680	Resistant Hypertension. <i>Hypertension</i> , 2017, 69, 582-583.	1.3	3
681	Response by Bakris to Letter Regarding Article, â€œThe Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressureâ€• <i>Circulation</i> , 2017, 135, e47.	1.6	3
682	Initial Singleâ€”Pill Blood Pressureâ€”Lowering Therapy: Should It Be for Most People?. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	3
683	High screen failure rate in patients with resistant hypertension: Findings from SYMPPLICITY HTN-3. <i>American Heart Journal</i> , 2017, 192, 76-84.	1.2	3
684	Intradialytic Hypotension: Is Midodrine the Answer?. <i>American Journal of Nephrology</i> , 2018, 48, 378-380.	1.4	3

#	ARTICLE	IF	CITATIONS
685	The Renin–Angiotensin–Aldosterone System and the Kidney. , 2018, , 27-41.		3
686	Comparison of the effects of dopamine and fenoldopam, a selective dopamine-1 agonist, on parathyroid hormone release in man. Mineral and Electrolyte Metabolism, 1988, 14, 343-6.	1.1	3
687	Treatment of renal failure and blood pressure. Current Opinion in Nephrology and Hypertension, 1997, 6, 237-242.	1.0	2
688	Choices and goals in the treatment of the diabetic hypertensive patient. Current Hypertension Reports, 2001, 3, 387-391.	1.5	2
689	Management of hypertension in the cardiometabolic syndrome and diabetes. Current Diabetes Reports, 2004, 4, 199-205.	1.7	2
690	Albuminuria and Cardiovascular Risk. Heart Failure Clinics, 2006, 2, 53-59.	1.0	2
691	Beta-Blocker Therapy in Hypertension: A Need to Pause and Reflect. Journal of the American College of Cardiology, 2008, 51, 516-517.	1.2	2
692	The Message for World Kidney Day 2009. Kidney and Blood Pressure Research, 2009, 32, 67-70.	0.9	2
693	Is blockade of the renin-angiotensin system appropriate for all patients with diabetes?. Journal of the American Society of Hypertension, 2009, 3, 288-290.	2.3	2
694	Lower Blood Pressure Goals in High-Risk Cardiovascular Patients: Are They Defensible?. Cardiology Clinics, 2010, 28, 447-452.	0.9	2
695	Newer renin–angiotensin–aldosterone system blocker combinations. Current Opinion in Nephrology and Hypertension, 2011, 20, 471-475.	1.0	2
696	A reappraisal of renin–angiotensin system blockade on microalbuminuria development. Journal of Hypertension, 2012, 30, 48-50.	0.3	2
697	Evidence-Based Triple Antihypertensive Therapy Yields Lower Mortality in Older Patients With Diabetes Mellitus. Hypertension, 2014, 63, 220-221.	1.3	2
698	Impact of blood pressure lowering in type 2 diabetes. Nature Reviews Nephrology, 2015, 11, 320-321.	4.1	2
699	Blood-Pressure Control. New England Journal of Medicine, 2015, 373, 2180-2182.	13.9	2
700	SGLT2 inhibitors: not just another glucose-lowering agent. Nature Reviews Nephrology, 2016, 12, 128-129.	4.1	2
701	Approach to Difficult to Manage Primary Hypertension. , 2018, , 281-287.		2
702	FO022BARDOXOLONE METHYL PREVENTS EGFR DECLINE IN PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 4 AND TYPE 2 DIABETES - POST-HOC ANALYSES FROM BEACON. Nephrology Dialysis Transplantation, 2018, 33, i10-i10.	0.4	2

#	ARTICLE	IF	CITATIONS
703	Kidney injury is not prevented by hydration alone. <i>European Heart Journal</i> , 2019, 40, 3179-3181.	1.0	2
704	Diastolic Blood Pressure Does Not Influence Cardiovascular Outcomes in Type 2 Diabetes; or Does It?. <i>Diabetes Care</i> , 2020, 43, 1684-1686.	4.3	2
705	Hyperkalemia Management in Older Adults With Diabetic Kidney Disease Receiving Renin-Angiotensin-Aldosterone System Inhibitors: A Post Hoc Analysis of the AMETHYST-DN Clinical Trial. <i>Kidney Medicine</i> , 2021, 3, 360-367.e1.	1.0	2
706	Successful treatment of refractory HTN with bilateral nephrectomy in a patient with CKD 3. CKJ: <i>Clinical Kidney Journal</i> , 2022, 15, 347-350.	1.4	2
707	Albuminuria reduction and nephropathy progression. <i>Current Hypertension Reports</i> , 2008, 10, 388-9.	1.5	2
708	Clonidine for opiate withdrawal. <i>Postgraduate Medicine</i> , 1982, 71, 240-241.	0.9	1
709	Chronic pain. <i>Postgraduate Medicine</i> , 1983, 73, 119-128.	0.9	1
710	Treatment of hypertension in the elderly: a review. <i>Geriatric Nephrology and Urology</i> , 1991, 1, 121-127.	0.4	1
711	Renal mortality associated with non-insulin-dependent diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 1997, 11, 104-111.	1.2	1
712	How to adjust ACE inhibitors and ARBs in diabetes?. <i>Postgraduate Medicine</i> , 2004, 115, 9-10.	0.9	1
713	Greater efficacy of chlorthalidone over hydrochlorothiazide for achieving blood pressure goals. <i>American Journal of Hypertension</i> , 2004, 17, S114.	1.0	1
714	Selection of explicit criteria for a JNC-7 guideline adherence tool. <i>American Journal of Hypertension</i> , 2004, 17, S144.	1.0	1
715	Physician adherence to JNC 7 guidelines and blood pressure control. <i>American Journal of Hypertension</i> , 2005, 18, A190-A190.	1.0	1
716	Are antihypertensive drugs associated with an increased risk of incident type 2 diabetes?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 8-9.	2.9	1
717	The Editor's Roundtable: Prehypertension. <i>American Journal of Cardiology</i> , 2009, 104, 1105-1115.	0.7	1
718	The message for World Kidney Day 2009: hypertension and kidney disease—a marriage that should be prevented. <i>Clinical and Experimental Nephrology</i> , 2009, 13, 96-99.	0.7	1
719	Corrigendum to “A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure” [Int. J. Cardiol. 137 (2009) 1–8]. <i>International Journal of Cardiology</i> , 2010, 145, 409.	0.8	1
720	Blood Pressure Targets in Diabetes: Is This the Time for Change?—CON (Rebuttal). <i>Journal of Clinical Hypertension</i> , 2011, 13, 268-269.	1.0	1

#	ARTICLE	IF	CITATIONS
721	Combination Therapy in Hypertension Treatment. , 2012, , 169-182.		1
722	Primary hypertension. , 2012, , 437-443.		1
723	Blood pressure goals in T2DM: a Latin American perspective. Nature Reviews Endocrinology, 2013, 9, 138-139.	4.3	1
724	Summary and Conclusions. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 23-23.	1.0	1
725	Blood pressure goals in T2DM â€” time for a rethink?. Nature Reviews Endocrinology, 2016, 12, 629-630.	4.3	1
726	Diabetes Care: â€œLagniappeâ€•and â€œSeeing Is Believingâ€†. Diabetes Care, 2016, 39, 1069-1071.	4.3	1
727	Hypertension control and cardiovascular disease â€” Authors' reply. Lancet, The, 2017, 389, 154-155.	6.3	1
728	Searching for the Optimal Blood Pressure Range in the Elderly. Journal of the American College of Cardiology, 2017, 69, 494-496.	1.2	1
729	AVERAGE CLINICIAN MEASURED BLOOD PRESSURE PREDICT CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES FOLLOWING ACUTE CORONARY SYNDROMES IN THE EXAMINE TRIAL. Journal of the American College of Cardiology, 2017, 69, 1676.	1.2	1
730	Severe menses-associated hypertension successfully treated with gonadotropin-releasing hormone agonist. Journal of Clinical Hypertension, 2017, 19, 1202-1203.	1.0	1
731	Blood pressure reduced to new guideline goals in patients with highâ€•normal glucose further reduces cardiovascular events. Journal of Clinical Hypertension, 2018, 20, 625-626.	1.0	1
732	Initial single-pill combinations for antihypertensive treatment: greater cardiovascular mortality reduction yet still not used. European Heart Journal, 2018, 39, 3662-3663.	1.0	1
733	Hypertension and Chronic Kidney Disease. , 2018, , 311-320.		1
734	Approach to the Patient with Hypertensive Nephrosclerosis. , 2020, , 737-752.		1
735	Improvement of Cardiovascular Functional Reserve After Kidney Transplantâ€”Has the CAPER Been Solved?. JAMA Cardiology, 2020, 5, 430.	3.0	1
736	Approach to Resistant Hypertension from Cardiology and Nephrology Standpoints. Cardiology Clinics, 2021, 39, 377-387.	0.9	1
737	Diagnosis, Prevention, and Treatment of Hypertensive Heart Disease. , 2014, , 51-58.		1
738	Cardiovascular Risk Assessment and Summary of Guidelines for the Management of Hypertension. , 2011, , 97-113.		1

#	ARTICLE	IF	CITATIONS
739	Carotid Baroreceptor Stimulation. Updates in Hypertension and Cardiovascular Protection, 2016, , 339-348.	0.1	1
740	Differential Effects of β -Blockers on Albuminuria in Patients With Type 2 Diabetes. Hypertension, 2005, 46, 1309-1315.	1.3	1
741	Diabetes Mellitus and Hypertension. Updates in Hypertension and Cardiovascular Protection, 2018, , 695-704.	0.1	1
742	Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension. American Journal of Hypertension, 2021, 34, 531-539.	1.0	1
743	Mineralocorticoid Receptor Antagonistsâ€™ Evidence for Kidney Protection, Trials With Novel Agents. Advances in Chronic Kidney Disease, 2021, 28, 371-377.	0.6	1
744	The message for World Kidney Day 2009: hypertension and kidney disease, a marriage that should be prevented. Iranian Journal of Kidney Diseases, 2009, 3, 7-10.	0.1	1
745	Calcium antagonists. Current Opinion in Cardiology, 1990, 5, 633-634.	0.8	0
746	Severe Hypertension in a Young Patient. Hospital Practice (1995), 1993, 28, 47-54.	0.5	0
747	The Medical Bookshelf. Postgraduate Medicine, 1993, 93, 14-14.	0.9	0
748	Symposium from the 1993 Annual Meeting of the American College of Clinical Pharmacology. Journal of Clinical Pharmacology, 1995, 35, 72-72.	1.0	0
749	Risks for renal involvement in diabetes. Postgraduate Medicine, 1998, 104, 33-33.	0.9	0
750	When to discontinue ACE inhibitors for nephropathy. Postgraduate Medicine, 1999, 106, 29-29.	0.9	0
751	20thâ€™Century Advances in Clinical Pharmacology. Journal of Clinical Pharmacology, 2000, 40, 907-907.	1.0	0
752	Roundtable Discussion: Problems in the Management of Hypertension. Journal of Clinical Hypertension, 2002, 4, 207-212.	1.0	0
753	When to refer patients to a nephrologist?. Postgraduate Medicine, 2003, 113, 11-11.	0.9	0
754	Best diagnostic approach to hyperkalemia?. Postgraduate Medicine, 2003, 114, 64-64.	0.9	0
755	Treatment of hypertension in patients with diabetes mellitus: initial losartan/hydrochlorothiazide combination versus ramipril monotherapy. American Journal of Hypertension, 2004, 17, S106-S107.	1.0	0
756	Effects of drospirenone/estradiol on blood pressure and serum potassium in hypertensive postmenopausal women at risk for hyperkalemia. American Journal of Hypertension, 2004, 17, S162.	1.0	0

#	ARTICLE	IF	CITATIONS
757	Optimizing target-organ protection in patients with renal impairment. American Journal of Hypertension, 2004, 17, S246-S247.	1.0	0
758	Clinical trials report. Current Hypertension Reports, 2006, 8, 395-397.	1.5	0
759	An Evidence-Based Practice Protocol for the Diagnosis and Management of Microalbuminuria in the Diabetic Patient. Journal for Nurse Practitioners, 2007, 3, 172-177.	0.4	0
760	Lifestyle changes and unanswered questions about hypertension and cardiovascular risk. Current Hypertension Reports, 2007, 9, 392-392.	1.5	0
761	Challenges to the Diagnosis, Evaluation, Treatment, and Management of Clustered Cardiometabolic Risk Factors. Journal of the Cardiometabolic Syndrome, 2008, 3, 119-125.	1.7	0
762	Response to "Diuretics should be used as the second-line agent in combination with RAS inhibitors in proteinuric patients with CKD". Kidney International, 2008, 74, 1358-1359.	2.6	0
763	The Message for World Kidney Day 2009. Nephron Clinical Practice, 2009, 111, c155-c158.	2.3	0
764	The Message for World Kidney Day 2009. Blood Purification, 2009, 27, 231-234.	0.9	0
765	ADVANCE: Blood Pressure Lowering in Diabetes. Journal of Clinical Hypertension, 2009, 11, 109-110.	1.0	0
766	Home blood pressure monitoring to manage hypertension in patients with nephropathy: The time has arrived. Current Hypertension Reports, 2009, 11, 299-300.	1.5	0
767	Hypertension guidelines and chronic kidney disease: Physicians, please follow directions. Current Hypertension Reports, 2009, 11, 301-302.	1.5	0
768	The future of blood pressure control in a population with a growing girth. Current Opinion in Nephrology and Hypertension, 2009, 18, 379-380.	1.0	0
769	Response to "Telmisartan is more effective than losartan in reducing proteinuria". Kidney International, 2009, 75, 120.	2.6	0
770	Leadership Message. Journal of Clinical Hypertension, 2010, 12, 631-632.	1.0	0
771	Hypertensive Kidney Disease. , 2010, , 57-67.		0
772	Forging Ahead with Lessons from the Past. American Journal of Nephrology, 2010, 31, H.	1.4	0
773	Overview of the KEEP international articles. Kidney International, 2010, 77, S1.	2.6	0
774	Preface. Cardiology Clinics, 2010, 28, xi.	0.9	0

#	ARTICLE	IF	CITATIONS
775	Assessment and management of vascular disease risk in patients with chronic kidney disease. Journal of Clinical Lipidology, 2011, 5, 251-260.	0.6	0
776	Leadership Message. Journal of Clinical Hypertension, 2011, 13, 533-533.	1.0	0
777	Author's reply: Inadequate sleep equates to inadequate BP control. Nature Reviews Cardiology, 2012, 9, 429-429.	6.1	0
778	Antihypertensive Therapy and New-Onset Diabetes. , 2012, , 121-127.		0
779	Novel Pharmacological Approaches in Hypertension Treatment. , 2012, , 175-184.		0
780	Hypertensive Goals in Patients with Coronary Artery Disease. Current Cardiology Reports, 2012, 14, 667-672.	1.3	0
781	Kidney Disease in Hypertension. , 2013, , 270-279.		0
782	Lowering blood pressure limits in patients with type 2 diabetes: Is it still warranted?. Journal of Diabetes and Its Complications, 2013, 27, 415-416.	1.2	0
783	Obesity, blood pressure, and cardiovascular outcomes – Authors' reply. Lancet, The, 2013, 381, 1982-1983.	6.3	0
784	The Role of Aldosterone in the Spectrum of Cardiovascular and Kidney Disease Risk: Introduction. Seminars in Nephrology, 2014, 34, 245-246.	0.6	0
785	Renal Denervation Therapy and Baroreceptor Activation Therapy: Emerging Tools for Treating Resistant Hypertension. , 2015, , 163-183.		0
786	Approach to the Patient with Hypertensive Nephrosclerosis. , 2015, , 455-469.		0
787	Cardiovascular Risk Assessment, Summary of Guidelines for the Management of Hypertension and a Critical Appraisal of the 2014 Expert Panel of the National Institutes of Health Report. , 2016, , 131-150.		0
788	MY APPROACH to the elderly patient with resistant hypertension. Trends in Cardiovascular Medicine, 2018, 28, 79-80.	2.3	0
789	Use of Combination Therapies. , 2018, , 261-267.		0
790	Presence of Diabetes Does Not Mandate Lower Blood Pressure to Reduce Cardiovascular Events. Journal of the American College of Cardiology, 2018, 72, 1224-1226.	1.2	0
791	Hyperkalaemia in diabetes: a silent risk predicting poor outcomes. Diabetic Medicine, 2018, 35, 1049-1050.	1.2	0
792	Hypertension and Diabetes. Endocrinology, 2018, , 1-22.	0.1	0

#	ARTICLE	IF	CITATIONS
793	Primary hypertension. , 2019, , 429-437.		0
794	Hypertensive Heart Failure: Sprinting to the Finish Line to Prevent End-Organ Damage. Heart Failure Clinics, 2019, 15, xiii-xv.	1.0	0
795	Paradoxical Cardiorenal Responses Following Acute Vasodilator/Natriuretic Treatment in Presystolic Heart Failure. JACC Basic To Translational Science, 2019, 4, 973-975.	1.9	0
796	Management of Hypertension in Diabetes Mellitus. , 2019, , 115-133.		0
797	An Unusual Case of Resistant Hypertension Secondary to Fibromuscular Dysplasia. JACC: Case Reports, 2020, 2, 2460-2464.	0.3	0
798	Fear of Lowering Cardiovascular Risk by Achieving Blood Pressure Goals. Hypertension, 2020, 75, 943-944.	1.3	0
799	Factitious acidosis and severe hypoalbuminemia caused by unsuspected assay interference. CKJ: Clinical Kidney Journal, 2021, 14, 1023-1024.	1.4	0
800	Systolic Blood Pressure During Exercise Testing: Where the Valley Means More Than the Peak. Hypertension, 2021, 77, 1915-1917.	1.3	0
801	Optimizing Blood Pressure Control Without Adding Anti-Hypertensive Medications. American Journal of Medicine, 2021, 134, 1195-1198.	0.6	0
802	Longitudinal Blood Pressure Patterns and Chronic Kidney Disease Progression: An Evolving Paradigm. Hypertension, 2021, 78, 1365-1367.	1.3	0
803	Oral antidiabetic agents safe with renal disease?. Postgraduate Medicine, 2000, 107, 66.	0.9	0
804	Should all patients with type 2 diabetes receive initial combination therapy: an assessment of the ADVANCE trial. Polish Archives of Internal Medicine, 2007, 117, 389-390.	0.3	0
805	Inhibiting the renin-angiotensin system in patients with type 1 diabetes: is it worth it?. Polish Archives of Internal Medicine, 2009, 119, 692-693.	0.3	0
806	Executive Summary: Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Laboratory Medicine Online, 2011, 1, 173.	0.0	0
807	The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol. Cardiovascular Therapy and Prevention (Russian Federation), 2011, 10, 116-121.	0.4	0
808	Hypertension and Diabetes. Endocrinology, 2018, , 109-130.	0.1	0
809	Hypertension and Diabetes. Endocrinology, 2019, , 1-22.	0.1	0
810	Hypertension and Diabetes. Endocrinology, 2020, , 109-130.	0.1	0

#	ARTICLE	IF	CITATIONS
811	Identifying resistant hypertension in the population: the devil is in the details. Canadian Journal of Cardiology, 2022, , .	0.8	0
812	Renal adaptation to the failing heart. Understanding the cascade of responses. Postgraduate Medicine, 1994, 95, 141-6, 149-50.	0.9	0
813	Is ethnicity a factor in choice of antihypertensive drug?. Postgraduate Medicine, 2005, 117, 40.	0.9	0
814	Clinical trials report. Combination drug treatment for hypertension with nondiabetic renal disease. Current Hypertension Reports, 2005, 7, 358-9.	1.5	0
815	Appropriate dose transition to a controlled-release formulation of carvedilol in patients with hypertension. Reviews in Cardiovascular Medicine, 2008, 9, 96-105.	0.5	0
816	Should a lower blood pressure goal and albuminuria reduction be mandated to slow hypertensive nephropathy?. Current Hypertension Reports, 2008, 10, 387-8.	1.5	0
817	The message for World Kidney Day 2009: Hypertension and kidney disease: a marriage that should be prevented. Archives of Iranian Medicine, 2009, 12, 102-5.	0.2	0
818	Hypertension and kidney disease: a combination that should be prevented. Nephrology News & Issues, 2009, 23, 42, 44, 46.	0.1	0
819	Chronic Kidney Disease in Type 2 Diabetes: Optimizing Glucose-Lowering Therapy. Journal of Family Practice, 2019, 68, S1-S6.	0.2	0
820	Stemming the Progression of Diabetic Kidney Disease: The Role of the Primary Care Clinician. Journal of Family Practice, 2020, 69, S81-S86.	0.2	0
821	The FIDELIO Study Podcast. Diabetes Therapy, 2022, , 1.	1.2	0
822	Captopril reduced progression of microalbuminuria in normotensive type 1 diabetes. ACP Journal Club, 1994, 121, 11.	0.1	0
823	Modifiable risk factors predicted the development of diabetic nephropathy. ACP Journal Club, 1997, 127, 17.	0.1	0
824	Editorial Cycles and Continuity of <i>Diabetes Care</i> . Diabetes Care, 2022, 45, 1493-1494.	4.3	0